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ABSTRACT
Title of Dissertation: Characterization and Regulation of Skn-Directed Autoimmune
Skin Lesions
Pamela J. Staton, Master of Science, 1978
Dissertation Advisor: Susan Jackman, PhD.
Department of Microbiology, Immunology and Molecular Genetics

In the Skn model of autoimmunity, pathogenic T cells sensitized to Skn epidermal

antigens (Skn-immune spleen cells or SIS cells) elicited disease in the form of skin
lesions when adoptively transferred into shaved immunoincompetent syngeneic adult

recipients (‘lesion-forming animals’) while concomitant injection of immunoregulatory

normal spleen cells at twice the concentration (2 x normal spleen cells or 2XNS cells) of
SIS cells significantly lessened lesion development (‘lesion-controlling animals’) by Day
7 post cell transfer. In a time-course RT-PCR cytokine analysis of skin from lesion-

forming and lesion-controlling animals, IL-7 mRNA was significantly elevated in lesion
controlling skin on Day 7 while no significant differences were observed for IL-2, IL-4,

IL-10, IL-12, IFN-y or TGF~p. The CD4^ T cell was identified as the immunoregulatory
cells within the normal spleen cell population which, when adoptively transferred,
significantly reduced lesion grade by Day 7 and were also associated with an elevated IL-

7 mRNA level in the skin. To determine whether IL-7 expression without cell cotransfer

could control skin lesion development, IL-7 was exogenously expressed in the skin of
lesion-forming animals using a topically-applied plasmid-IL-7 somatic gene therapy.

Daily application of plasmid-IL-7 facilitated by brushing at sites that flanked the known
viii

reactive site for lesion development significantly reduced lesion severity which was
observed to be comparable to that observed with cotransfer of 2XNS or CD4-enriched
normal spleen cells.

plasmid-IL-7

The absence of endogenous IL-7 mRNA in lesion-controlling

recipients

indicated

that

plasmid-IL-7

mediated

lesion

control

independently of endogenous IL-7. Exogenous-IL-7 mRNA expression in the skin was

associated with a downregulated expression of endogenous IL-7 messages suggesting
that an IL-7 homeostatic mechanism existed in the skin responsive to plasmid-IL-7
therapy.

Furthermore, plasmid-IL-7 mRNA expression in the skin did not appear to

disrupt the cytokine milieu of the skin or to work in concert with other cytokines
analyzed. While others have reported a regulatory role for CD4+ T cells, this represents
the first report of a topically applied somatic gene delivery of IL-7 in the skin of mice

resulting in the control of autoimmune skin lesions.

ix

INTRODUCTION
Autoimmunity is a pathologic state wherein the normal self-tissues of the host are
targets of immune attack. Autoimmune disease can arise as a result of several factors

such as antigen mimicry, failure in deletion or control of autoreactive T cell clones or
aberrant cytokine production. The organ-specific diseases encompass a broad range of

conditions to include rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple
sclerosis, and Crohn’s disease. In addition, skin diseases with an autoimmune component

include psoriasis, lichen planus, pemphigus, vitiligo and alopecia areata. As there is no

known cure for these diseases or conditions, treatment currently focuses on alleviation of
symptoms. For example, diabetics are given frequent injections of insulin to compensate

for the destruction of their insulin-secreting cells while patients with rheumatoid arthritis
may be given steroids to reduce the painful inflammation associated with the disease.

These treatments fail to get to the root of the problem, as they do not correct the
fundamental immune defect that leads to pathology, and are often associated with serious

systemic side effects.
What incites an autoimmune reaction continues to elude investigators and

undoubtedly is a multifactorial process. Much effort has been committed to identifying
predisposing major histocompatibility complex alleles and other associated immune
response genes that predispose to the development of particular autoimmune diseases.

Without a known cause or means to predict who might develop these diseases, another
approach is to study the role of regulatory cells and immunomodulatory proteins, such as
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cytokines, on disease pathogenesis. A better understanding of effector cell activation and
control can provide information with respect to underlying immune response mechanisms

while potentially leading to new therapeutic options for human autoimmune disease.
Although animal studies using systemic administration or expression of

immunomodulatory proteins provides a rationale for investigating the potential of gene
therapy in autoimmune disease, systemic administration (Margolin et al., 1989) or

overexpression (Rich et al., 1993) of cytokines has had catastrophic effects, suggesting
that the administration of cytokines, or factors interfering with cytokine function, needs
to be on a local basis and tightly regulated. Gene therapy may offer solutions to the

problems of cytokine administration. Furthermore, plasmid-based somatic gene therapy
has several advantages that include ease of production and administration, localized
expression and, as a transient transfection, minimal opportunity for incorporation into the

host cell genome. As gene therapy is in its infancy, such alternative treatment approaches
to autoimmune disease intervention should be investigated.
The skin is a favorable organ for the study of immune regulation. As the largest

organ of the body, the skin serves as a physical barrier in addition to having a

complicated internal immunologic defense function. The skin’s ability to heal, as well as

to distinguish self from non-self, is challenging to the imagination when one considers
the physical, chemical and microbial trauma sustained by this protective sheath. The skin

plays a prominent role in immune regulation through the immune functions of cytokine
producing keratinocytes, antigen-presenting Langerhans cells, resident epidermal and

dermal T lymphocytes, vascular and lymphatic endothelial cells, and skin-draining lymph

2

nodes (Bos, 1997). While immune cells and associated immunomodulatory proteins play
a protective role in the skin, when dysregulated they also participate in the pathology

associated with autoimmune disease progression.
The Skn model of autoimmunity is an excellent model for studying autoimmune
■

regulation as 1) the epidermal target, i.e. murine Skn antigens, has been identified, 2) it
represents a CD4’r T cell induced phenomenon, 3) it is expressed in the skin which can be
easily monitored and biopsied, and 4) it can be induced in non-genetically modified

animals. In the Skn model of autoimmunity, animals are shaved to provide a mild trauma
to the skin and regulatory T cells depleted or dysregulated by cyclophosphamide treatment
(Barrett et al., 1995).

In these mice, administration of an adequate number of Skn-

immune spleen cells (SIS cells) results in the development of shaved-site-restricted
autoimmune lesions. Shaved animals receiving SIS cells without immunosuppression with
cyclophosphamide do not develop lesions suggesting that SIS cells are regulated in vivo.

The hypothesis of this study was that Skn-directed autoimmune skin lesions, and therefore

autoimmune Skn-immune spleen cells, are controlled or regulated in vivo by immune cells

and cytokines.

The objective or specific aim of this study was to create a Skn-directed

autoimmune response in the skin of B6AF1 mice and to evaluate the ability of immune
cells to mediate lesion control. Should lesion control be observed, the skin would then be

analyzed for selected cytokine mRNA expression. Cytokine messages determined to be
significantly elevated in lesion-controlling skin would be targeted for use in a topical gene

therapy to demonstrate the cytokine’s ability to mediate lesion control.
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LITERATURE REVIEW
Regulatory T Cells in Autoimmunity
Upon antigen encounter, the immune system can either develop an immune
response or enter a state of unresponsiveness called tolerance. When tolerance to self
antigens is broken, autoimmune disease develops. While clonal deletion of autoreactive T

cells in the thymus is fundamentally important for the induction of tolerance, it cannot be
the sole mechanism for tolerance maintenance. In the early 1970’s, it was discovered that

the unresponsive state could be transferred to normal syngeneic mice simply by the
transfer of T cells. In vivo experiments performed over the next 30 years provide
compelling data that supports the existence of suppressor T cells (Shevach, 2000).

Reconstitution experiments in the study of autoimmune thyroiditis (Kojima et al., 1976),

gastritis (Kojima et al., 1980) and oophoritis (Sakaguchi et al., 1982) strongly imply that

disease is prevented by suppressor T cells. Futhermore, it has been demonstrated that the
removal of suppressor T cells from otherwise normal animals resulted in disease and that
reconstitution of the suppressor T cell population could reestablish self-tolerance and

prevent autoimmunity (Sakaguchi et al., 1985). However, with the discovery of Thl/Th2
cells and their associated cytokine profiles, many investigators abandoned the concept
that suppressor T cells were a specialized population and proposed instead that
suppression was merely the result of the regulatory activity of cytokines. Only recently

has there been a resurrection of the concept that the suppressor T cell, derived from a

4
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unique lineage of cells, mediates downregulatory functions by a variety of effector

mechanisms.
For many years, cyclophosphamide has been used for the selective depletion of

suppressor T cell function in vivo (Barrett et al., 1995) as has thymectomy and
irradiation.

Using these techniques, it was demonstrated that normally autoreactive

effector and suppressor cells could coexist suggesting that certain autoimmune responses
are held in check by the equilibrium favoring suppressor activity (Penhale et al., 1973;
Penhale et al., 1975; Penhale et al., 1976). Later, in studies of organ-specific autoimmune
disease, CD4+CD8’ cells were identified as both the effector and the suppressor T cell
populations.

While CD4* suppressor cells appeared to be important for peripheral self

tolerance, it was also apparent that tissue-specific factors played a fundamental role in the

development of organ-specific immune function (Barrett et al., 1995).

Cytokines as Immune Response Regulators
Virtually every nucleated cell type in the body can produce regulatory peptides

known as cytokines. Involved in host defense and repair processes, cytokines have
pleiotropic effects on hematopoietic and many other cell types. Most cytokines act over

short distances as autocrine or paracrine intercellular signals that are generated in
emergencies to contend with challenges to the host integrity and to maintain homeostasis
by regulating the immune system. Imbalances in the production and action of cytokines

and/or their receptors will disturb homeostatic processes and have pathological
consequences.

While beneficial when regulated, cytokines can be viewed as double-

5

*

edged swords threatening the host when their production and actions are unregulated

(Stricter et al., 1995; Dinarello, 1996).

Most studies of cytokine action have been carried out in vitro with homogeneous
cytokine preparations produced by recombinant DNA techniques that have led to the
assembly of an enormous body of information on the spectrum of actions displayed by

individual cytokines (Burke et al., 1993). Although this information is important, it may
not provide a realistic picture of the functions of cytokines in vivo as cytokine behavior
can be influenced profoundly by the milieu in which they act (Spom et al., 1988). Under

in vivo conditions, any cell can be exposed to a cocktail of cytokines with the resulting
biological action reflecting various synergistic and antagonistic interactions. The skin is

composed of a wide variety of nucleated cell types representing a diverse source of

cytokines with immune regulatory potential. Also, when provoked, the skin can recruit
cells from the peripheral blood that bring with them the potential to produce an even
greater array of cytokine actions. Therefore, to characterize the cytokine milieu of the

skin in the Skn-model of autoimmunity, a battery of cytokines for in vivo evaluation was
selected based on their reported immunoregulatory potential and effect in modulating

autoimmune activity.

Interleukin 2 (IL-2)
IL-2 is produced principally by activated T cells and acts in an autocrine manner
to promote the rapid clonal expansion of effector T cell populations, as well as

directly affecting the growth and differentiation of B cells, natural killer (NK)

cells, lymphokine-activated killer (LAK) cells, monocytes, macrophages and

6

oligodendrocytes (Gaffen et al., 1998). In addition to its growth promoting
function, IL-2 also stimulates T cells to produce other cytokines including IFN-y
(Farrar et al., 1982) or IL-4 (Howard et al., 1983) associated with a Type-1 (T
helper 1/ Thl) response characteristic of many organ-specific autoimmune
diseases or a Type-2 (T helper 2/Th2) immunosuppressive response, respectively.

Experiments with mice bearing targeted deletions in IL-2 or its receptor
components (IL-2Ra, P and y) have indicated that in vivo IL-2 serves to prevent
autoimmunity and to maintain homeostasis of the immune system. While IL-2

deficient mice exhibit normal T cell development, approximately 50% of IL-2"
mice die between 4 and 9 weeks and those that survive develop an ulcerative
colitis-like disease raising the possibility that IL-2 production normally impedes
the emergence of this disease (Sadlack et al., 1993). Like IL-2

animals, the

absence of IL-2Roc or IL-2Rp gene products results in an autoimmune phenotype
and disruption in immune homeostasis (Grabstein et al., 1994; Suzuki et al.,

1995). This is supported in studies demonstrating that CD47IL-2R" T cells could
suppress the response of CD4VIL-2R* effector cells in coculture (Takahashi et al.,
1998) while transfer of CD47IL-2R+ cells could prevent autoimmune disease
development in thymectomized neonatal mice (Asano et al., 1996).

Interleukin 4 (IL-4)
The overall properties of IL-4 suggest a powerful and direct anti

inflammatory effect by virtue of its ability to downregulate the Thl proinflammatory response. The protective and anti-inflammatory roles of IL-4 have
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been demonstrated in various animal models of autoimmune disease whose

pathology is at least partially based on uncontrolled inflammation.

In particular.

the treatment of experimental autoimmune encephalomyelitis (EAE) by retinoids

that increase IL-4 production (Racke et al., 1995) or by IL-4 expressing
encephalitogenic T cells (Shaw et al., 1997) that allow local delivery of IL-4

markedly improved the time course of disease. Similarly, the chronic destructive
phase of arthritis in rat (Allen et al., 1993) or mouse (Bessis et al., 1996) models
can be efficiently countered by direct administration of IL-4 or by treatment with
IL-4 secreting cells. In addition, the protective effects of IL-4 have also been

reported in the nonobese diabetic (NOD) mouse model of insulin-dependent
diabetes mellitus (IDDM) (Rapoport et al., 1993; Yamamoto et al., 2001).
Recent data suggest that the generation and maintenance of tolerance to

self-antigens may be facilitated by a subset of T cells referred to as T regulatory

cells (Tr cells).

In a virus-induced model of autoimmune diabetes, protection

from disease afforded by Tr cells induced by oral insulin feeding was abrogated in
mice genetically deficient for IL-4 (Homann et al., 1999).

In other studies.

administration of anti-IL-4 monoclonal antibodies blocked the effect of

CD4^CD45RC’ peripheral cells or CD4~ thymocytes essential to the prevention of
autoimmune thyroiditis in thymectomized rats (Seddon et al., 1999). In addition,
IL-4 was shown to be required for induction of oral tolerance in experimental

autoimmune uveitis (Rizzo et al., 1999). These studies demonstrated a role for IL4 in the generation or regulation of a subset of Tr cells and established its
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importance as a growth factor for these cells rather than as an effector cytokine
(Roncarolo et al., 2000).

Despite the obvious protective effects of IL-4 in autoimmune disease, IL-4

generation is not always sufficient to protect from other autoimmune conditions.
In studies of experimental autoimmune encephalomyelitis (EAE), Th2 cells, an

excellent source of IL-4, were reported to cause the disease (Lafaille et al., 1997)
although mice treated with IL-4 at the time of transfer of encephalitogenic T cells

were protected from EAE (Racke et al., 1994; Rocken et al., 1996). Taken
together, the apparent contradictory effect of IL-4 in EAE may indicate that the
time of administration may be a factor in the cytokine control of EAE and other

autoimmune diseases.

Interleukin 10 (IL-10)
IL-10 was discovered as a ‘cytokine synthesis inhibitory factor’ produced
by mouse Th2 cells which inhibited cytokine production by activated Thl clones

while activated macrophages are another source of IL-10.

Like IL-4, a main

function attributed to IL-10 is its anti-inflammatory effect. This is clearly
demonstrated by IL-10 deficient (IL-107') mice that manifest severe inflammatory

bowel and other exaggerated inflammatory responses (Berg et al., 1995a; Berg et
al.,

1995b).

In

experimental

autoimmune

encephalitis

(EAE),

in

vivo

administration of IL-10 (Rott et al., 1994) or IL-10 producing T cells (Stohlman et

al., 1999) can inhibit initiation of disease while IL-10 has also been shown to be

effective in preventing relapses of EAE (Issazadeh et al., 1996).

9

Like IL-4,

administration of IL-10

may act by impairing the effector function of

autoreactive T cells (Buer et al., 1998).
In contrast, IL-10 has also been tested in several animal models of

autoimmune disease to exhibit an inflammatory pathology. For example, IL-10
expressed under the islet-specific promoter, accelerated IDDM development in

transgenic NOD mice (Wogensen et al., 1993; Lee et al., 1994; Moritani et al.,

1994; Wogensen et al., 1994; Balasa et al., 1996; Lee et al., 1996; Moritani et al..
1996). In EAE, IL-10 had no effect or exacerbated the severity of disease in mice

(Cannella et al., 1996). IL-10 gene therapy has supported the confusing role of
this cytokine in EAE (Mathisen et al., 1997; Shaw et al. 1997).

In a recent

comparison of IL-10 delivery systems to the central nervous system by
intracranial injection (Croxford et al., 2001), delivery via retroviral vectors

inhibited EAE whereas delivery by adenovirus vectors failed to inhibit disease.

While different outcomes were observed for the different delivery systems,

interestingly, the IL-10 protein levels were similar suggesting that the action of
IL-10 may differ depending on the local cytokine environment produced by the

gene-secreting cell types as injection of retroviral engineered IL-10-expressing
fibroblasts were more successful in treating EAE. While it is not clear why IL-10

exhibits these apparently contradictory effects, it is conceivable that IL-10 has

both pro- and anti-inflammatory properties or works in concert with other
cytokines (Zeller et al., 1999) to exert its immunosuppressive effect.
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Interleukin 12 (IL-12)

IL-12, produced principally by monocytes, macrophages and dendritic
cells, was initially identified and isolated as a natural killer (NK) cell stimulating

factor (Kobayashi et al., 1989).

However, IL-12 also has a major role in

promoting T-cell mediated immunity through activation (Gately et al., 1991;
Trinchieri, 1994) and differentiation (Gately et al., 1992) of cytotoxic T cells or

the generation of Thl cells (Manetti et al., 1993; Trinchieri, 1993).

Early

decisions made toward development of Thl- or Th2- type cells in the immune
response is dependent on the balance between IL-12, which favors Thl responses,
and IL-4, which favors Th2 responses (Trinchieri, 1993). Unlike most cytokines.
biologically active IL-12 is a heterodimeric protein composed of a heavy chain

(p40) and a covalently associated light chain (p35) (Stem et al., 1990).
Administration of IL-12 induces premature onset of IDDM, involving
pancreas-infiltrating CD4" cells that are exclusively of the Thl type, and increases

Thl responses to IDDM-associated autoantigens (Trembleau et al., 2000) while

administration of an IL-12 antagonist prior to the onset of insulitis results in

deviation of pancreas-infiltrating CD4r cells to the Th2 phenotype and reduction
of spontaneous and cyclophosphamide-accelerated IDDM (Rothe et al., 1997;
Trembleau et al., 1997). Administration of IL-12 antibodies was successfully used
to treat autoimmune diseases such as EAE (Leonard et al., 1995) and
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experimental colitis (Neurath et al.. 1995) while IL-12 expression is associated
with disease in other organ-specific autoimmune disease models (Trembleau et

al., 1995). In mycobacteria associated type II collagen-induced arthritis (CIA), IL12 was shown to replace the need for mycobacteria in disease development

(Germann et al., 1995). Conversely, high doses of IL-12 injected systemically
inhibited the development of disease in the same animal model (Hess et al., 1996)

suggesting a bimodal role for this cytokine in disease development. Although it is

not clear why IL-12 exhibits these apparently contradictory effects, IL-12, as seen
with IL-10 and IL-4, may have both pro- and anti- inflammatory properties

(Lamont et al., 1996).
Interferon gamma (IFN-y)

IFN-y is an important cytokine for the development of T cell mediated
immune responses. With respect to Thl and Th2 responses, IFN-y inhibits the
proliferation of Th2 cells indicating that during an immune response the presence
of IFN-y will result in the preferential expansion of Thl cells (Gajewski et al.,
1988).

In diabetes-prone NOD mice, IFN-y is overexpressed in inflamed

pancreatic islets and administration of soluble IFN-yR is protective (Nicoletti et
al., 1996). Furthermore, development of diabetes in NOD-sczd recipients

correlates with a rapid increase in peripheral CD45RB1OW CD4+ cells with a
significantly higher IFN-y to IL-4 ratio when compared to CD45RB1OV' CD4' cells

from nondiabetic mice (Shimada et al., 1996).

In the multiple low-dose

streptozotocin-induced or in the cyclophosphamide-accelerated NOD model of
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diabetes, intramuscular gene transfer of IFN-yR-encoding plasmid has been

shown to prevent insulitis and diabetes (Chang et al., 1999; Prud'homme et al..
1999).

While the presence of IFN-y is detrimental in most autoimmune diseases
(Kalden et al., 1998) (De Maeyer, 1998) the specific role IFN-y plays in

autoimmunity remains unclear.

For example, in IFN-y deficient nonobese

diabetic (NOD) mice, the development of diabetes was delayed but the frequency

of disease presentation appeared to be the same as in normal NOD control mice

(Hultgren et al., 1996). Similarly, in other conditions thought to have an
autoimmune component such as inflammatory bowel disease (IBD) to include

ulcerative colitis and Crohn’s disease (MacDermott et al., 1988; Podolsky 1991;

Podolsky 1991; Braegger et al., 1994), IFN-y is thought to be important for
initiating but not necessarily for sustaining CD4" Th-dependent colitis.

example, the treatment of neonatal IL-10’

For

mice with anti-IFN-y mAb

dramatically delays the onset and reduces the severity of disease while similar
treatment had no effect on established disease in adult animals (Berg et al., 1996;

Fort et al., 1998).
While IFN-y would appear to have some detrimental role in the initiation
and/or progression of autoimmune disease, this has not been the case with

experimental allergic encephalomyelitis (EAE) (Kalden et al., 1998). In EAE,
removal of IFN-y is known to exacerbate T-cell mediated autoimmune disease
(Willenborg et al., 1996).

Interestingly, IL-10+IFN-y"IL-2lowIL-4‘ regulatory T
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(Tr) cells have been induced from naive CD4* T cells (Levings et al., 2001)

suggesting that INFy may act in concert with other cytokines to mediate different
immunologic effects.

It has also been observed that several regulatory T cell

populations seem to require IFN-y to exert their downmodulatory effect on the

pathogenesis of T-cell-mediated autoimmune diseases (Kumar et al., 1998;
Falcone et al., 1999a). Surprisingly, transgenic expression of IFN-y in the

pancreatic islets can actually reduce the diabetogenic potential of autoreactive T

cells and prevent IDDM in streptozotocin-treated mice (Gu et al., 1995).
Transforming Growth Factor- Beta (TGF-0)

There is considerable evidence for an immunomodulatory role of TGF-P
and its function as a potent immunosuppressive agent (Letterio et al., 1998). T

lymphocytes are strongly regulated by TGF-p. TGF-P is now known to also exert
a multiplicity of biologic activities on many non-immune cells by regulating
physiologic processes in a cell-type-dependent manner. TGF-P has clear bimodal
effects, with low and high concentrations exerting distinctively different

physiologic effects (Rook et al., 1986; Centrella et al., 1987; Battegay et al., 1990;
Gorham et al., 1998). TGF-P may also work in conjunction with other cytokines

to mediate its immunosuppressive effects. In cotransfer experiments, IL-10 and

TGF-p in combination were shown to have an additive effect in suppressing CD4’

T cell mediated antigen-specific responses (Zeller et al., 1999). The pretreatment
of CD4" T cells with IL-10 plus TGF-p, but neither alone, resulted in markedly

impairing induction of graft versus host disease upon transfer. Therefore, acting
14
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alone or in concert with other regulatory cytokines, TGF-pi expression is most

often associated with an anti-inflammatory, immunosuppressive effect.
In the skin, TGF-P is a potent inhibitor of epithelial cell and keratinocyte

proliferation (Massague et al., 1995) while transgenic overexpression of TGF-p in
mouse skin has revealed a more complex role for TGF-P in skin proliferation.

Consistent with the antiproliferative effect of TGF-P on keratinocytes, epidermal

overexpression of active TGF-p 1 in HK.l-TGF-P 1 transgenic mice results in a

hypokeratotic epidermis with strongly inhibited proliferation (Sellheyer et al.,

1993). In addition, increased epidermal proliferation is seen in TGF-p 1 knockout
mice (Glick et al., 1993) and in mice in which a truncated version of the type II

TGF-P receptor is overexpressed (Wang et al., 1997).

In contrast, suprabasal

transgenic expression of TGF-p 1 from the keratin 10 promoter results in

increased basal cell proliferation suggesting a positive effect of TGF-P 1 on
epidermal cell proliferation (Cui et al., 1995; Fowlis et al., 1996).

These

contradictory findings may possibly be attributed to quantitative differences in

TGF-p overexpression associated with promoter-driven transgene expression in
these animals. In addition to the role of TGF-P in regulating keratinocyte

proliferation, TGF-P is also known to regulate Langerhans cells in the epidermis

and follicular dendritic cells of the lymph nodes by protecting their viability
(Strobl et al., 1996; Riedl et al., 1997) while an absence of epidermal Langerhans
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cells is seen in TGF-P-deficient mice (Borkowski et al., 1996; Borkowski et al..

1997).
Strong support exists for the role of TGF-P in autoimmune disease. In
EAE, TGF-P-producing T cells were shown to inhibit autoreactive T cell

responses (Karpus et al., 1989).

In other models, exogenous administration of

TFG-p in vivo markedly depresses inflammatory and immunologic responses
prolonging the time to rejection of rat islet transplants (Carel et al., 1990; Carel et
al., 1993), delays the onset of EAE (Kuruvilla et al., 1991; Racke et al., 1992) and

experimentally induces arthritis (Brandes et al., 1991; Thorbecke et al., 1992). In
addition, increased levels of TGF-P in the synovial fluid of joints of patients with

rheumatoid arthritis is observed (Wahl et al., 1988; Lotz et al., 1990; Wilder et al.,
1990) in association with suppressed cellular responsiveness resembling the
inhibited responsiveness of lymphocytes and macrophages from experimental
chronic arthritis mice (Wahl et al., 1988).

Interleukin 7 (IL-7)
IL-7 is a uniquely non-redundant cytokine (von Freeden-Jeffry et al.,

1995) in which targeted gene deletion of IL-7 results in severe defects in

lymphoid development (Peschon et al., 1994). Principal effects of IL-7 include
promotion of pre-B cell proliferation, T lymphocyte growth and differentiation.

and lymphokine-activated killer (LAK) cell generation (Alderson et al, 1990;
Grabstein et al., 1990; Grabstein et al., 1993). IL-7 is constitutively expressed by

both primary (Sakata et al., 1990; Welch et al., 1990; Cumano et al., 1991) and

16

secondary lymphoid organs (Namen et al., 1988; Goodwin et al., 1989), as well as

non-lymphoid cells including skin keratinocytes (Heufler et al., 1993), intestinal
epithelial cells (Watanabe et al., 1995) and brain (Michaelson et al., 1996). IL-7

has also been reported to be produced by fibroblasts (Aiba et al., 1994; Buske et
al., 1994), peripheral blood mononuclear cells (Lum et al., 1994) such as

monocytes (Sieling et al., 1995), B-lymphocytes (Benjamin et al., 1994) and

dendritic cells (Moore et al., 1993; Funk et al., 1995; Kroncke et al., 1996; Sorg et
al., 1998).

While IL-7 is an essential maintenance and survival factor for

immature thymocytes (Murray et al., 1989), in vitro, IL-7 is also known to
increase the survival and proliferation of mature T cells (Grabstein et al., 1990;

Maraskovsky et al., 1996; Vella et al., 1997; Hassan et al., 1998). While early
reports suggested IL-7 to be important as a growth factor for activated, but not

resting, T cells (Namen et al., 1988; Chazen et al., 1989; Morrissey et al., 1989;

Alderson et al., 1990), more recent reports have identified IL-7 as essential for

resting T cell survival (Vella et al., 1997), expansion (Schluns et al., 2000) and
enhancement of naive CD4+ T cell longevity in vivo (Boursalian et al., 1999).

Reports of the beneficial effects of IL-7 administration have been

numerous. In cyclophosphamide or irradiation treated mice, IL-7 administration
has been shown to accelerate lymphocyte repopulation (Morrissey et al., 1991;
Faltynek et al., 1992) while in humans, IL-7 has been shown to facilitate CD4 T
cell repopulation in lymphopenic hosts including HIV patients (Fry et al., 2001).

Transgenic expression of IL-7 has also been demonstrated to restore T cell
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populations in nude mice (Rich et al., 1995), to accelerate bone marrow transplant

engraftments (Boerman et al., 1995) and to induce anti-tumor activity by
alteration of T cell subsets and enhanced T cell function (Komschlies et al., 1994),

all of which demonstrate the potential therapeutic efficacy of IL-7 in vivo. It has
also been shown that culturing epidermal T cells in the presence of IL-7 causes
increased adhesion of these cells to the major epidermal basement membrane

(Wagner et al., 1999) suggesting that IL-7 may play a role in epidermal T cell
entry into the epidermis. In addition, IL-7 has been shown to promote a Th2

cytokine pattern in cultured CD4r T cells (Webb et al., 1997).

On the other hand, the detrimental effects of IL-7 overexpression have
been seen most clearly in IL-7 transgenic animals where keratinocyte-promoter
driven IL-7 transgenic mice develop a cutaneous disorder characterized by T-cell

proliferation (Williams et al., 1997) with progression to lymphoma (Rich et al.,

1993).

While these observations support a detrimental effect of IL-7

overexpression, IL-7 was not determined to be overexpressed in skin samples of

patients with cutaneous T-cell lymphoma (Asadullah et al., 1996). In another IL7 transgenic animal under the control of the SRa promoter known to be expressed

by many cell lines (Rich et al., 1993), over 50% of the mice that expressed the
transgene developed severe dermatitis with lesions predominantly infiltrated by

CD4’CD8‘ bearing the y6 T cell receptor. Spleens and lymph nodes from these
animals were also observed to contain large numbers of yd TCR cells (Uehira et
al., 1993). RT-PCR and flow cytometric analysis revealed that dermis infiltrating
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lymphocytes expressed various cytokines including IL-4 and IL-7 and several

activation markers for T cells suggesting that these cells were in an activated state
in the skin lesion and produced Th2 type cytokines (Uehira et al., 1998).
Dendritic epidermal T cells (DETCs), which are CD3\ CD4‘, CD8', y8 TCRJ, are

one member of a family of yd T cells that reside preferentially in epithelial tissues
(Bergstresser et al., 1993). In normal mouse epidermis, IL-7 has been shown to

promote DETC growth with an inhibition of keratinocyte growth by IFN-y
produced by DETC (Matsue et al., 1993; Takashima et al., 1996) suggesting that
IL-7 may play a role in the control of keratinocyte hyperproliferative states. In

studies of human psoriasis characterized by a hyperproliferation of the epidermis,

some investigators were unable to detect IL-7 mRNA in the skin of psoriasis
patients (Asadullah et al., 1996) while others reported increased levels of IL-7 in
human psoriatic skin lesions (Bonifati et al., 1997) making it unclear whether IL-7

plays a role in the control or perturbation of this skin related disorder.

The Role of ThO, Thl, Th2, or Th3 Cytokine Profile in the Induction and Control of

Autoimmunity
As autoimmune disease is undoubtedly a multifactorial process, important to the

understanding of these diseases is a clearer understanding of the roles of immunologic,

environmental and genetic factors involved in the generation, activation and expansion of
self-reactive T cells. Animal models of autoimmunity have shown that many autoimmune
diseases can be transferred to naive animals using CD4+ antigen-specific T cells that
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secrete Thl cytokines such as IFN-y, IL-2 and tumor necrosis factor (TNF) (van der Veen
et al., 1993). CD4" Thl T cells represent a T helper cell subset with an inflammatory
cytokine profile (i.e. secretion of IFN-y and TNF) and effector functions important for

inflammatory cellular immune responses while Th2 cytokines such as IL-4 and IL-10
may be important for disease recovery as Th2 autoantigen-specific T cells have been

shown to accumulate in the target organ in the recovery phase of disease (Khoury et al..

1992). Regulatory Th3 and Tri cells have also been described which exert their

regulatory potential through the secretion of the immunosuppressive cytokines TGF-P
and/or IL-10 (Chen et al., 1994; Bridoux et al., 1997; Shi et al., 1999; Doetze et al., 2000;

Kitani et al., 2000).

Although it remains unclear as to whether Th3 and Tri cells

represent different Tr cell subsets (Roncarolo et al., 2000).

Nevertheless, cytokines

produced by fully differentiated Th cells are known to have counterregulatory effects on

their Th counterparts which suggests that the cytokine milieu is critical in shaping
immune responses and may be sufficient by itself to dictate the outcome of T cell
differentiation (Seder et al., 1994).
In contrast, Th2 CD4+ T cells can also mediate autoimmune disease. Thyroiditis,

an organ-specific disease, was precipitated in mice by the transfer of a CD4T clone that

produced IL-4 and IL-10, but not IFN-y or IL-2. Upon stimulation with thyroglobulin.

polymorphonuclear cells in the thyroid rather than the more typical mononuclear cells
associated with Thl CD4+ T-cell involvement were observed (Hiyama et al., 1993). In
addition, while the colitis suppressive effect of CD45RB1OU cells in vivo could be

counteracted by the administration of antibody to IL-4, IL-10 or TGF-P (Powrie et al.,
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1996) (Seddon et al., 1999), in vitro addition of antibody to IL-4, IL-10 or TGF-P alone.

or in any combination, failed to reverse suppression suggesting that distinct suppressor
cell populations may differ in their mechanism of action. With respect to regulation of

effector cell responses, alteration of differentiated CD4’ T cell function appears to be

somewhat unlikely as demonstrated in studies using transcription factors specific for
polarized Th cells which were unable to significantly alter the cytokine secretion of the

effector cells (Ouyang et al., 1998). However, it does appear possible to affect effector

function and differentiation of ThO or naive cells, and possibly memory CD4" T cells that

are not completely differentiated (Secrist et al., 1993; Bradley et al., 1995). Therefore,

identifying factors, such as cytokines that may dictate subset differentiation, may provide
useful information for treatment of many disease states to include autoimmunity. While

the balance of antigen-specific Thl/Th2 cells may dictate the clinical outcome of an

autoimmune disease, the factors that define an environment in which cells differentiate

into mature Th cells are not well understood (Nicholson et al., 1996). Cytokines exert the
most dominant influence on Th cell differentiation. Although autoimmunity was once

recognized as being synonymous with the development of disease, it is now clear that the
relative contribution of T-helper cells to the developing autoimmune response is

associated with the expression of autoimmunity as either a destructive or a non
destructive process. By modulating the immune response, it is then possible to regulate
the development of clinical autoimmune disease. The possibility of using regulatory T

cells in the treatment of human autoimmune disease relies heavily on elucidating the
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mechanisms of induction and function of these cells while cytokine therapy designed to

boost the endogenous pool of Tr cells can also be envisaged.

Skn Model of Autoimmunity

To study an autoimmune response in the skin, Skn antigens expressed on
epithelial cells can be used as targets to generate a skin-restricted autoimmune response

for the study of immune dysregulation (Jackman et al., 1992). Skn antigens are encoded
by two unlinked genes, Skn 1 and Skn 2, each with alternative alleles in various strains of

mice (Goldberg et al., 1990). Skn antigens are localized selectively to mouse epidermal

(Scheid et al., 1972; Jackman et al., 1987; Jackman et al., 1989) and neuronal cells
(Scheid, et al. 1972; Rees, et al. 1993). Monoclonal antibody raised against Skn 2

identifies a murine 95 kDa protein (Jackman et al., 1987; Rees et al., 1993). This protein
probably has a human equivalent, in as much as the anti-Skn 2 antibody recognizes a

similar sized

molecule

in human

epidermal

cells

(E.H.

Goldberg,

personal

communication).
The products of the Skn genes are sufficient to elicit an immune response (Boyse

et al., 1968; Wachtel, 1977; Fleming et al., 1981). The Skn alloantigens of the mouse

were first identified when lethally irradiated C57BL/6 (B6) mice restored with B6AF1
bone marrow or spleen cells were demonstrated to invariably reject A and B6AF1 skin

grafts while accepting B6 donor skin grafts (Warner et al., 1965; Boyse et al., 1968). In
this system, the lethally irradiated B6 mouse is reconstituted with B6AF1 spleen cells to
generate a chimera in which the hematopoietic system is of B6AF1 origin while the rest
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of the mouse is B6. As the host skin antigens are of the B6 type, the chimera can be

sensitized and subsequently reject an A strain skin graft based on non-self skin specific
antigens representing the A strain Skn alleles.

Rejection of A strain skin grafts is

associated with the production of antibody that reacts with A skin epidermal cells without
reacting with A hematopoietic cells or B6 skin further demonstrating the allelic and tissue

specificity of Skn (Scheid et al., 1972).
The tissue-restricted expression of Skn alloantigens emphasizes the potential of

the Skn-model of autoimmunity.

When Skn-sensitized B6AF1 spleen cells from

chimeras who have rejected the A skin graft are transferred to a normal B6AF1 host.
these chimera-generated Skn-immune spleen (SIS) cells have the potential to initiate a

skin-directed autoimmune response. The Skn-model of autoimmunity thus provides a
means by which autoimmune regulatory components can be studied at the macroscopic,

microscopic and molecular level. It has been further demonstrated that SIS cells are
tightly regulated because no skin-directed lesions form without prior immunosuppression

of the recipients while lesions form only in areas of mild skin trauma (Jackman et al.,

1992). The multifactorial character of the Skn model of autoimmunity demonstrates the
powerful potential of the skin immune system to exquisitely regulate deleterious
autoimmune responses. Furthermore, dose-related transfer of primed Skn-immune cells

correlates with autoimmune disease severity, CD4" T cells within the Skn-immune cell
population are responsible for disease development and the cytokine profile of lesional

skin resembles the Th-1 cytokine response (S.H. Jackman unpublished data).
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Biology and Gene Therapy of Autoimmune Disease

Cytokines, as host mediators in response to invading organisms, tumors and trauma, are
being evaluated for their efficacy in the treatment of a wide variety of infectious and

autoimmune diseases and neoplasms. While autoimmune diseases can be ameliorated by

treatments with regulatory cytokines, inflammatory cytokine inhibitors, monoclonal
antibodies to costimulatory molecules, or other immunomodulatory molecules (Kalden
et al., 1998; Theofilopoulos et al., 1999; Prud’homme et al., 2001), successful treatment

with these proteins has been minimized by rapid turnover of the product and antibody

production against antigenic components.
Gene

therapy

may

be

a

viable

alternative

to

administration

of

immunomodulatory proteins. Although gene therapy is in its infancy, several studies

have been met with some success. Retroviral vectors have been successfully used for ex
vivo transfer of genes into autoantigen-specific T cells for selective infiltration into target
organs upon adoptive transfer (Seroogy et al., 2000). For example, IL-4, delivered to the

central nervous system via ex vzvo-retroviral transduction of autoreactive T cells, has
been shown to block EAE development (Shaw et al., 1997). Success has also been seen in
the treatment of diabetes in the nonobese diabetic mouse model where adoptive transfer

of pancreatic islet-specific Thl clones transfected with retroviral vectors encoding IL-10

led to the suppression of diabetes as well as a decrease in IFN-y mRNA (Moritani et al.,
1996).

Similarly, most epidermal gene transfer studies have focused on ex vivo

approaches (Fenjves et al., 1989; Palmer et al., 1989; Fenjves et al., 1994) to include a
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study of genetically modified keratinocytes shown to reconstitute the epidermis after
being transplanted to wound sites to facilitate wound healing (Vogt et al.. 1994). While

an important research tool in deciphering the role of immunomodulatory proteins in
autoimmune disease progression, the use of viral vectors for the purposes of gene therapy

have some limitations including risk of contamination, recombination with helper viruses
as well as complex production methods (Prud'homme et al., 2001).

In addition, anti-

vector immune responses can provoke local or systemic inflammatory reactions to

prevent expression or readministration of the vector (Bromberg et al., 1998). While the

use of such viral vectors has provided important information in demonstrating use of
cytokines in the control of autoimmune disease, their clinical utility is compromised by

the need to use the patient’s own cells to avoid allogeneic reactions and the requirement

for T cells of appropriate specificity to be generated resulting in inherent delays and risk
of failure.
Nonviral intramuscular gene therapy expressing cytokines or their respective

receptors has also been successful in the experimental treatment of autoimmune disease.

Autoimmune diabetes has been prevented by intramuscular gene therapy with a nonviral

vector encoding an IFN-yR/IgGl fusion protein (Prud'homme et al., 1999). Intramuscular
administration of expression plasmids encoding IFN-yR/IgGl, IL-4/IgGl (Chang et al.,

1999) or IL-10 (Nitta et al., 1998) was shown to protect from IDDM in the NOD mouse
model. In addition, cDNA encoding IFN-yR/Fc has shown promise in the treatment of

murine lupus (Lawson et al., 2000) while TGF-pi somatic gene therapy has also been

shown to prevent IDDM in the NOD mice (Piccirillo et al., 1998), to prevent EAE
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(Piccirillo et al.. 1999) and to suppress chronic disease in the streptococcal cell wall-

induced arthritis model (Song et al., 1998).
Several methods have been developed to deliver cloned genes into the skin in

vivo. Using noncationic liposome complexes and a lacZ expression plasmid, the lacZ
gene product was detected in hair follicles (Li et al., 1995). In a cationic liposome: lacZ

expression vector topically applied onto mouse skin previously treated with a depilatory
cream, P-galactosidase was detected in the dermis, epidermis and hair follicles

(Alexander et al., 1995).

Delivery of DNA into the skin without carriers has also been

reported via direct injection into the skin of experimental animals (Furth et al., 1995;
Hengge et al., 1995; Ciemik et al., 1996), by gene gun (Williams et al., 1991), or by

. electric pulse (Zhang et al., 1996). All of these methods resulted in the expression of the
transferred genes in the epidermis and dermis. Despite these encouraging results, little is

known about the principles of cutaneous gene transfer.

While localized intradermal

injection and electric pulse have limited clinical relevance, Yu et al. (1999) described a
clinically relevant gene delivery method which demonstrated expression of reporter genes

in the epidermis and hair follicles when naked plasmid DNA was applied topically to
mouse skin (Yu et al., 1999).

An efficient, yet noninvasive, topical cutaneous gene

delivery system where expression could be largely limited to the epidermis may represent
a useful approach to targeting cytokines to the skin in a clinically relevant manner.

While immunomodulatory gene therapy approaches appear promising for the
treatment of autoimmune disease, cytokine effects in vivo are complex and some

contradictory or unexpected findings have been observed suggesting that a far more
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complex situation exists than the simple Thl versus Th2 dualism (Kalden et al.. 1998;
Theofilopoulos et al., 1999; Prud’homme, 1993). Dose and/or time of administration

relative to disease onset or induction, and method and/or site of administration, are

important to the success or failure of any cytokine treatment (Song et al., 1998:
Theofilopoulos et al., 1999; Prud'homme et al., 2000; Croxford et al., 2001). While in the
early stages of research and development, immunogene therapy has an immense potential

for disease prevention and treatment.
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MATERIALS AND METHODS
Mice.

Female C57BL/6J (B6), A/J (A), and (C57BL/6JxA/J)Fl/J [B6AF1] mice were

obtained from The Jackson Laboratory, Bar Harbor, ME. All mice were conventionally

housed in accordance with National Institutes of Health guidelines and all experiments

approved by the Institutional Animal Care and Use Committee of Marshall University.

The Skn Autoimmune Mouse Model
Radiation Chimeras. B6AF1/B6 radiation chimeras were produced by irradiation of B6
mice with 1150 rads using a Theratron 1000 cobalt 60 unit (Theratronics International

Limited, Kanata, Ontario, Canada).

This dose was shown to have an LDioo of 14 days

for B6 mice (S.H. Jackman and E.H. Goldberg unpublished data). Within a few hours
after irradiation, mice were intravenously reconstituted with 0.2 ml suspension of 40 x

106 B6AF1 spleen cells in saline. Mice were subsequently treated with penicillin (90

units) and streptomycin (90 p.g) i.p. every second day for 3 weeks. Chimerism was

confirmed by periodic testing of lymph node cells by flow cytometry with H-2a (A strain)
and H-2b (B6 strain) antisera, which invariably demonstrated the donor’s hematopoietic

system to be of the B6AF1 phenotype.

Eight weeks post-irradiation, chimeras were

immunized by skin grafting with A strain tail skin (Boyse et al., 1970; Jackman et al..
1987). At least six-weeks post-immunization, Skn-sensitized spleen cells were collected
from the chimeras for use in adoptive and cotransfer experiments.

Pretreatment of B6AF1 Mice.

One day prior to cell transfer (day -1), mice were

anesthetized using brief inhalation of ether (Fisher Scientific, Fair Lawn, NJ) or Metofane
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(Mallinckrodt Veterinary Inc., Mundelein, IL) followed by clipping of the dorsal skin of

B6AF1 mice using Oster animal shears (Oster Professional Products, McMinnville. TN)
and subsequent shaving with a Gem blade razor to remove all traces of superficial hair.

The following day, animals received 200 mg/kg body weight of cyclophosphamide
(Neosar, Pharmacia & Upjohn Company, Kalamazoo, MI) at 4 hours (Day 0 -4h) via tail

vein administration.

Adoptive Transfer of SIS Cells for the Generation of Autoimmune Lesion-Forming

Animals. Spleen from B6AF1/B6 chimeras having previously rejected A strain skin grafts

were minced in sterile phosphate-buffered saline (PBS), filtered through a 40p.m nylon
mesh (SEFAR America Inc., Kansas City, MO), and washed by centrifugation at 700 x g at

4°C for 10 minutes in PBS. The supernatant was removed and cells [hereafter denoted as
Skn-immune spleen (SIS) cells] reconstituted for counting.

The trypan blue exclusion

method (Strober, 1997) was used to enumerate viable cells using a hemacytometer with
Neubauer rulings.

A final concentration of 50x106 SIS cells in 0.1 ml PBS was

administered intravenously by tail vein injection into pretreated B6AF1 recipients (Day 0,
Ohr).
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Lesion Grade Assessment. Gross lesions were graded by two independent investigators
based on the following criteria:
Grade
0
1

2
3
4
5

Description
No lesion visually detected. Skin appears normal at target site.
Skin scaling or dry flaking skin at target site.
Erythema observed without pitting at target site.
Erythema and pitting over less than 50% target site.
Erythema and pitting >50% but <100% of target site.
Erythema and pitting over 100% of target area.

Histopathology. Histopathology was assessed on sections of paraffin-embedded skin.

Sections were stained with hematoxylin and eosin.

Slides were evaluated for the

presence of hyperkeratosis, acanthosis, parakeratosis, pustular crusts, ulceration and the

presence of epidermal, dermal and adipose layer cellular infiltrates. Tissue sections were
evaluated independently by a pathologist and a basic science investigator.

Adoptive Transfer of SIS Cells

+ Normal B6AF1 Spleen [2XNS] Cells for the

Generation of Autoimmune Lesion-Controlling Animals.

Spleens were aseptically

removed from B6AF1 mice, minced in sterile PBS, filtered through a 40 pm nylon mesh,

and washed by centrifugation at 700 x g at 4°C for 10 minutes in PBS. The supernatant
was removed and cells reconstituted for counting. B6AF1 cells were stained with trypan

blue, cell viability assessed, and cells reconstituted in a final concentration of lOOxlO6

normal spleen [2XNS] cells/ 0.1 ml sterile PBS. SIS cells were administered to shaved
and cyclophosphamide treated B6AF1 mice as previously described. Four hours post

cyclophosphamide injection, mice received a tail vein injection of 50x106 SIS cells in
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addition to lOOxlO6 B6AF1 normal spleen [2XNS] in a total combined volume of 0.2 ml
in PBS on Day 0.

T cell enrichment and depletion procedures: Common procedure: The StemSep

procedure (StemCell Technologies, Inc., Vancouver, British Columbia, Canada) was used

to collect the desired cells for cotransfer experiments and was as follows.
technique was observed for all cell enrichment or depletion steps.

Aseptic

Normal B6AF1

spleens were removed and single cell preparations achieved by mincing in sterile PBS

without calcium or magnesium with 5% fetal bovine serum (Life Technologies,

Gaithersburg, MD) followed by filtration through a nylon mesh as previously described.
Cells were collected by centrifugation at 700 x g for 10 min at 4°C and resuspended in
PBS without calcium or magnesium with 5% fetal bovine serum for counting.

Cell

viability was assessed using the trypan blue exclusion method and enumerated using a
hemacytometer with Neubauer rulings. Cells were resuspended in sterile PBS without

calcium or magnesium with 5% fetal bovine serum and 5% rat serum (StemCell
Technologies) at a concentration of 80x106 nucleated cells/ ml and incubated in one of

the antibody cocktails listed below for 15 minutes at 4-8°C. StemSep columns (StemCell
Technologies) were prepared as described by the manufacturer.

Following the final

wash, PBS was added to the column matrix. Following cell incubation, the cell-antibody
mixture was washed in 5% fetal bovine serum containing PBS without calcium and
magnesium by centrifugation at 700 x g for 10 minutes at 4°C followed by resuspension

of the cells for counting.

After adjustment of cell concentrations to 80x106 cells/ml,
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anti-biotin tetrameric antibody complexes (StemCell Technologies) at lOOpl/ml were
added followed by the addition of 60 pl of magnetic colloid (StemCell Technologies) per
ml.

Following incubation, three ml of the mixture was added to a washed column

positioned in a rare earth magnet and cells were allowed to flow through the column. The

flow-through fraction plus 3 washes with PBS were collected.
CD4 T cell enrichment.

The CD4

T cell enrichment antibody cocktail

(StemCell Technologies) contained biotinylated antibodies to CDllb (Mac-1),
CD45R (B220), CD8, myeloid differentiation antigen (Gr-1) and erythroid cells
(TERI 19).

CD8 T cell enrichment:

The CD8" T cell enrichment antibody cocktail

(StemCell Technologies) consisted of biotinylated antibodies to CD4, CD45R

(B220), CDllb (Mac-1), myeloid differentiation antigen (Gr-1), erythroid cells

(TER 119), and NK cells (DX5).

CD4 T cell depletion:

The CD4+ T cell depletion cocktail (StemCell

Technologies) consisted of biotinylated antibody to CD4.
CD8 T cell depletion:

The CD8+ T cell depletion cocktail (StemCell

Technologies) contained biotinylated antibody to CD8.

Flow Cytometric Analysis of Enriched and Depleted Cell Populations. To determine
the success of cell enrichment or depletion procedures, 50pl aliquots of the resultant
flow-through cell populations at lxl06/ml were independently stained with 20pl of the
following fluorescently-labeled antibody suspensions: phycoerythrin (PE)-labeled anti-
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CD4 (BD PharMingen, San Diego, CA) or fluoroscein isothiocyanate (FITC)-labeled
anti-CD8 antibody (BD Pharmingen) for 30 min on ice. Cells were washed twice in 2.5

ml PBS and cell pellets resuspended in 2% paraformaldehyde for flow cytometric

analysis using a FACScan Flow cytometer and Cell Quest Software (FACScan, Bectin
Dickinson, San Jose, CA).

In Vitro Culture of Regulatory B6AF1 Cells in rIL-7. Spleens from B6AF1 mice were
minced for single cell collection. Twenty x 106/ml unfractionated or CD4-enriched

normal spleen cells were cultured in RPMI 1640 culture medium supplemented with

Glutamax and 10% fetal bovine serum (both from Life Technologies), 0.05 miM p-

mercaptoethanol, penicillin (100 lU/ml), streptomycin (100 |ig/ml) and 1000 U/ml

murine rIL-7 (R&D Systems Inc., Minneapolis, MN). After 60 hours of culture at 37°C
in a humidified atmosphere containing 5% CO2, cells were recovered by centrifugation at

700 x g for 10 minutes. Cells were then resuspended in sterile PBS and the trypan blue
exclusion method was used to adjust cell numbers for cotransfer.

Flow Cytometry of Regulatory Cells Before and After Culture in IL-7. Before and

after culture in rIL-7, unfractionated and CD4-enriched B6AF1 normal spleen cells were
stained and analyzed, as described above, with fluorescently labeled antibodies to CD3

(fluorescein isothiocyanate-conjugated hamster anti-mouse CD3 monoclonal antibody;
clone 500-A2; Caltag Laboratories, Burlingame, CA), CD4 (R-phycoerythrin-conjugated

rat anti-mouse CD4 monoclonal antibody; clone GK1.5; Phamingen), and CD8a
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(fluorescein isothiocyanate-conjugated rat anti-mouse CD8a; clone 53-6.7; Pharmingen).
A three-step staining procedure was performed for CD 127 (IL-7R) cell staining

consisting of purified rat anti-mouse CD 127 monoclonal antibody (clone Bl2-1;
Pharmingen), biotinylated rabbit anti-rat IgG (Vector Laboratories Inc. Burlingame, CA)

and streptavidin-conjugated to

fluorescein isothiocyanate (Vector Laboratories).

Fluorescently labeled cells were evaluated by single color FACScan flow cytometric

analysis using Cell Quest Software (Bectin Dickinson).

Total RNA Isolation.

Tissue was snap frozen in liquid nitrogen and stored at -70°C

prior to RNA extraction. Trizol (Life Technologies) was used for tissue homogenization

using either a Tekmar Tissumizer (Tekmar, Cincinnati, OH) or a Mini BeadBeater using

2.5 mm zirconia beads (BioSpec Products, Bartlesville, OK).

RNA was isolated using

the procedure described by the manufacturer of Trizol. After a brief room temperature
incubation to permit complete dissociation of nucleoprotein complexes, chloroform

(Sigma Chemicals, St.Louis, MO) was added followed by a room temperature incubation.
Samples were centrifuged at 4°C and the upper aqueous/RNA phase collected. RNA was

precipitated by mixing the collected fraction with isopropyl alcohol and collected by
centrifugation at 4°C. The visible RNA pellet was then washed with 75% ethyl alcohol

and collect by centrifugation followed by a brief period for drying. RNA was solubilized
in RNA Storage Solution (Ambion, Austin, TX) and solubilized by heating at 60°C.

RNA

quantitation via

A26O/28O ratio

was determined
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using

a

Beckman

DU

Spectrophotometer. RNA was stored at -70°C or used immediately in the reverse
transcriptase reaction.

Reverse Transcription of Total RNA.

Two micrograms of RNA was added to a

reaction mix which consisted of IX buffer [from 10X PCR Buffer II: 100 mM Tris-HCl,
500 mM KC1, pH 8.3 at 25° C] (Perkin Elmer, Foster City, CA), 3 mM MgCb (Perkin

Elmer), 2 mM dNTP (Perkin Elmer), 1.5 pM oligo d(T)i6 (Marshall University DNA

Core Facility), 1 unit/pl RNase inhibitor (Life Technologies), and 13.3 units/pl Maloney
Murine Leukemia Virus (MMLV) reverse transcriptase (Life Technologies).

RT

reactions were incubated for 1 hr at 60°C, 10 minutes at 80°C, and 1 minute at 4°C.

Completed reactions or cDNAs were used immediately in the polymerase chain reaction
or stored at -70°C for subsequent analysis. For tissues taken from animals receiving

plasmid-IL-7, duplicate reaction mixes were used with the exception that one contained

reverse transcriptase (RT positive) and the other contained no reverse transcriptase (RT
minus) while all other conditions remained constant as stated above.

Polymerase Chain Reaction of cDNA. Four microliters of cDNA were amplified in a

polymerase chain reaction mixture consisting of IX buffer, 1.2 mM MgCh, 0.2 mM of
each dNTP, 5 units Taq polymerase (Perkin Elmer) and 0.4 pM of the appropriate primer
pair.

Samples were amplified in a MJ Research PTC-200 Peltier Thermal Cycler (MJ

Research, Inc. Waltham, MA) with the following cycling conditions: 45 sec at 95°C, 45
sec at 60°C, 1 min at 72°C for 35 cycles with a final extension for 7 min at 72°C. PCR
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products were electrophoresed on a 2.75% agarose gel (1.83% Nusieve GTG agarose;

0.92% SeaKem GTG agarose, BioWhittaker Molecular Applications, Rockland, ME),
stained with ethidium bromide (Sigma Chemicals) and net intensity determined using a
Kodak Digital Science Electrophoresis Documentation and Analysis System 120

(Eastman Kodak Company, Rochester, NY). Cytokine bands were normalized to p actin
for comparison by the formula: cytokine net intensity divided by p actin net intensity.

Cytokine primer pairs were synthesized in the Core Facility, Marshall University,

Huntington, WV and used in the polymerase chain reaction as follows:

3’ IL-2
5’ IL-2
3’ IL-4
5’ IL-4
3’ IL-7
5’ IL-7
3’ IL-10
5’IL-10
3’IL-12p35
5’ IL-12 p35
3’ IL-12 p40
5’ IL-12 p40
3’ IFN-y
5’ IFN-y
3’ TGF-p
5’TGF-p
3’ P Actin
5’ P Actin
3’ FLAG-IL-7
5’ FLAG-IL-7

GACAGAAGGCTATCCATCTCCTCAGAAAGTCC
TTCAAGCTCCACTTCAAGCTCTACAGCGGAAG
CAGTGATGTGGACTTGGACTCATTCATGGTGC
CCAGCTAGTTGTCATCCTGCTCTTCTTTCTCG
CAGGAGGCATCCAGGAACTTCTG
GCCTGTCACATCATCTGCGTGCC
ATTTCGGAGAGAGGTACAAACGAGGTTT
ATGCAGGACTTTAAGGGTTACTTGGGTT
CAAGGCACAGGGTCATCATC
ACCTCAGTTTGGCCAGGGTC
GAACACATGCCCACTTGCTG
AACTGGCGTTGGAAGCACGG
TGGACCTGTGGGTTGTTGACCTCAAACTTGGC
TGCATCTTGGCTTTGCAGCTCTTCCTCATGGC
TGGAGCTGAAGCAATAGTTGGTATCCAGGGCT
TGGACCGCAACAACGCCATCTATGAGAAAACC
CTCTTTGATGTCACGCACGATTTC
GTGGGCCGCTCTAGGCACCAA
GATTACAAGGATGACGACGAT
TCGGGCAATTACTATCAGTTC
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For tissues derived from plasmid-IL-7 recipients, net intensity of the ‘RT positive’ band

was subtracted from the net intensity of the ‘RT minus’ band to compensate for the
presence of plasmid in these samples. The remainder was then divided by the [3 actin
band net intensity to achieve the plasmid-derived IL-7 mRNA value.

IL-7 Immunohistochemistry.

Skin tissues were embedded in O.C.T. Compound

(Tissue Tek, Sakaura Finetek U.S.A. Inc., Torrance, CA) and stored at -70°C. Tissues

were cryosectioned at a lOpim thickness using a Leica cryostat (Leica Cryocut 1800,
Leica

Microsystems,

Inc.

Bannockbum,

IL)

onto

Laboratories) slides that were stored at -20°C until used.

V ectabond-coated

(Vector

All staining reactions were

performed at room temperature in a humidified chamber as previously described
(Jackman et al, 1989) with some modifications. On the day of staining, the sections were
brought to room temperature, acetone-fixed and endogenous peroxidase activity blocked

with 1.5% hydrogen peroxide in methanol. Tissue sections were then incubated in 10%

normal rabbit serum, treated with avidin and biotin blocking reagents (Vector
Laboratories) followed by an overnight incubation with purified goat anti-mouse IL-7
antibody (R&D Systems) at 4°C in a humidified chamber. The following day, slides

were washed in PBS and incubated in biotinylated anti-rabbit antibody (Vector

Laboratories), followed by a wash and incubation in Vectastain Elite ABC Reagent
(Vector Laboratories) at room temperature. Following incubation, slides were washed in

PBS and incubated with the peroxidase substrate, diaminobenzidine tetrahydrochloride
(Vector Laboratories), and counterstained with hematoxylin. Slides were examined for
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an IL-7 antibody-specific reddish/brown color development while slides treated with PBS

in place of primary antibody were examined for a negative color reaction.

IL-7 cDNA.

The murine IL-7 cDNA in a BlueScript KS vector was a gift from

Benjamin E. Rich (Brigham and Women’s Hospital, Division of Dermatology, Harvard

Institutes of Medicine, Boston, MA); the IL-7 coding sequence (Appendix A) is as
follows:

5’-ATG TTC CAT GTT TCT TTT AGA TAT ATC TTT GGA ATT CCT CCA CTG

ATC CTT GTT CTG CTG CCT GTC ACA TCA TCT GAG TGC CAC ATT AAA

GAC AAA GAA GGT AAA GCA TAT GAG AGT GTA CTG ATG ATC AGC ATC
GAT GAA TTG GAC AAA ATG ACA GGA ACT GAT AGT AAT TGC CCG AAT
AAT GAA CCA AAC TTT TTT AGA AAA CAT GTA TGT GAT GT ACA AAG

GAA GCT GCT TTT CTA AAT CGT GCT GCT CGC AAG TTG AAG CAA TTT

CTT AAA ATG AAT ATC AGT GAA GAA TTC AAT GTC CAC TTA CTA ACA
GTA TCA CAA GGC ACA CAA ACA CTG GTG AAC TGC ACA AGT AAG GAA
GAA AAA AAC GTA AAG GAA CAG AAA AAG AAT GAT GCA TGT TTC CTA
AAG AGA CTA CTG AGA GAA ATA AAA ACT TGT TGG AAT AAA ATT TTG

AAG GGC AGT ATA TAA-3’

pCMV-FLAG-IL-7 Fusion Construct and Plasmid Purification.

The murine IL-7

cDNA sequence was amplified to create Bglll and Xhol restriction sites for digestion and

subsequent insertion into the pCMV-Tagl mammalian expression vector (Stratagene,
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LaJolla, CA).

The forward PCR primer, which incorporated a BgUI site, was 5’-

C ACCTCC AGATCTCC ATGTTCC ATGTTTCT-3 ’.

The

reverse

primer.

which

incorporated a Xhol site, was 5’- TATACTGCCCTCGAGAATTTTATTCC-3'. The IL7 amplification product and the pCMV-Tagl vector, were digested with BgUI and Xhol
restriction endonucleases (Promega, Madison, WI) for directional insertion of the IL-7

cDNA into the pCMV-Tagl vector and subsequent ligation using a standard ligation
reaction. A perfect Kozak sequence, (CCACCATGG), an N-terminus FLAG coding
sequence (GATTACAAGGATGACGA CGATAAG), kanamycin resistance gene and

stop codon were provided by the pCMV-Tagl vector. Ligated plasmid or control vector
was isolated by transformation of DH5a competent cells (Life Technologies) followed by

streaking for isolated colonies on 0.005% kanamycin (Life Technologies)-containing

20g/L Luria Bertani (LB) broth and 12g/L Select Agar (both, Gibco BRL, Life

Technologies) plates. Following an overnight incubation at 37°C, single colonies were

selected for plasmid amplification and purified using the Endofree Plasmid Maxi Kit
(Qiagen. Valencia, CA) and the manufacturer’s procedure followed. After a brief drying

period, the DNA pellet was redissolved in TE Buffer and stored at 4°C. This preparation
was sequenced using T3/T7 primers (5’-AATTAACCCTCACTAAAGGG-3 ’ and 5’-

GTAATACGACT CACTATAGGGG-3’, respectively) and a dideoxy sequencing
program to verify the presence and correct orientation of the IL-7 cDNA. Based on

nucleotide sequence analysis, the IL-7 cDNA clone used in these experiments was
determined to be in the appropriate orientation and contained no mutations that would

result in amino acid changes. Plasmid control consisted of the pCMV-Tagl vector
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containing a firefly luciferase gene cloned into the Bgl II/Xho I site (Stratagene) so that

the luciferase protein was tagged with the FLAG epitope at the N terminus.

Transfection of C2 Cells with PIasmid-IL-7 Construct.

Adherent C2 mouse muscle

cells (courtesy of Todd Green, Marshall University, Huntington, WV) were transfected

with Lipofectin Reagent (Life Technologies) following the manufacturer’s directions.
Briefly, in separate reaction solutions, 2 pg of plasmid DNA or 20 pl of Lipotectin
Reagent (Life Technologies) was diluted in 100 pl of OPTI-MEM I Reduced Serum

Medium (Life Technologies), the solutions combined and then added to C2 cells

previously washed with OPTI-MEM I Reduced Serum Medium. Cells were incubated
for 24 hours at 35°C in 5% CO2. Medium was removed, replaced with DMEM with 5%

FBS (Gibco BRL, Life Technologies) and incubated for 72 hours. Supernatant was
collected for use in the IL-7 bioactivity assay of 2E8 cells (TIB-239 FL; American Type
Culture Collection, Manassas, VA) as described in the Results.

IL-7 Somatic Gene Therapy. Animals were anesthetized using a combination of
i.p.injection of ketamine (Ketaset, Fort Dodge Animal Health, Fort Dodge, Iowa) and
brief inhalation of ether. On Day -1, dorsal hair was clipped on B6AF1 animals with

Oster animal shears to include A, B, C, D and E sites as described in the Results. In
addition, all superficial hair was removed from the A and B sites using a Gem blade
razor. The designated plasmid target site was gently brushed 100 strokes with a nylon,

round-bristled toothbrush. A 20 pl sample containing plasmid-IL-7 in TE buffer
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(Qiagen) was placed in the center of the site with an Eppendorf pipettor and the side of
the pipette tip used to distribute the plasmid over the central area of the site. Animals

remained anesthetized for approximately 10 minutes following plasmid application or
until no liquid was observed on the skin surface.

Statistical Analysis. Statistical analysis was conducted using the Mann-Whitney U test.

Results are given as mean + standard error of the mean.
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RESULTS
PROGRESSIVE AUTOIMMUNE SKIN LESIONS FORM WHEN
THREE CONDITIONS ARE MET
In B6AF1 mice, autoimmune skin lesions develop in a site-restricted manner

when three conditions are met, namely 1) mild trauma to the skin by shaving, 2) induced

immunosuppression by cyclophosphamide, and 3) tail vein administration of 50x106 Sknimmune spleen cells (SIS cells). Lesions do not form when one or more of these essential

components are omitted, thus defining the Skn model of autoimmunity (Jackman and
Goldberg, 1992).

In this model, lesions occured only at the shaved-site and gross

pathology was graded on a scale of 0 to 5. A grade of 0 was given when no lesion could
be visually detected. A lesion grade of 1 was assigned when skin scaling or flakiness was
observed without erythema or pitting, while a grade of 2 was assigned when erythema or

pitting was observed but not both.
degree of erythema and pitting.

Lesion grades of 3 through 5 demonstrated some

A grade of 3 was recorded when both erythema and

pitting covered <50% of the target site, a grade of 4 when erythema and pitting covered

>50% but <100% of the target site, while a lesion grade of 5 covered the entire shaved-

site area.

Figures la-If are representative of lesion grades 0 through 5 in animals

developing Skn-directed autoimmune skin disease.
To induce Skn-directed skin lesion formation, B6AF1 mice were shaved on Day
minus 1 and received cyclophosphamide immunosuppression at 4 hours prior to the

administration of 50x106 SIS cells on Day 0. All mice formed lesions at the site of shaved
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skin by Day 7. Animals in which one or more of the essential conditions was omitted

showed no lesion formation by Day 7 (Table 1).
In B6AF1 mice receiving shaving, cyclophosphamide immunosuppression and

SIS cells, lesions were observed to develop in a progressive fashion with the most severe

lesions seen at the termination of the experiment on Day 7 (Figure 2). As lesions
invariably formed when this protocol was followed, these animals are, henceforth,

referred to as ‘lesion-forming animals.’
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Figure 1

Definition of Gross Pathology
Grade

Definition

Figure

0

No lesion visually detected
at the shaved skin site.

la

1

Scaling or dry flaking
skin at the shaved skin site.

lb

2

Erythema or pitting observed
at the shaved skin site.

1c

3

Erythema and pitting observed
over less than 50% of the shaved
skin site.

Id

4

Erythema and pitting observed
over more than 50% but less
than 100% of the shaved skin site.

le

5

Erythema and pitting observed
to cover 100% of the shaved skin
site.

If
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Table 1
Skn-Directed Skin Lesions Form When

Three Conditions Are Met
Where indicated, B6AF1 mice received dorsal shaving on Day -1, cyclophosphamide at
200 mg/kg body weight (i.v.) 4 hours prior to the administration of 50x106 SIS cells on

Day 0. Skin lesions observed at the shaved skin site were graded on Day 7 post-cell
transfer.
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Table 1

Experimental Conditions
Day -1: dorsal shaving_______
Day 0 - 4h: cyclophosphamide
DayO: 50x10b SIS cells
Day 7 mean lesion grade
No. animals per group______
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+
+
+

+

X5
14

0
9

+
+

+

+

0
10

+
0
2

0
3

Figure 2

Skn-Directed Skin Lesions Form in a Progressive Fashion
B6AF1 mice received shaving on Day -1 and an intravenous administration of 200
mg/kg cyclophosphamide 4 hours prior to the administration of 50x106 SIS cells on Day
0. Lesions were graded daily for 7 days post-cell transfer. Bars represent mean lesion

grade and standard error for that day. Data represent 14 animals from 5 different

experiments. Linear regression analysis resulted in a correlation coefficient of 0.89.
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HISTOPATHOLOGIC FEATURES OF AUTOIMMUNE SKN LESIONS
Murine skin consists of two main layers, the surface epithelium or epidermis, and

the subjacent connective tissue layer, the dermis.

Beneath the dermis is a looser

connective tissue layer, the superficial facia, which in many places is largely transformed

into subcutaneous adipose tissue. The outer surface of the epithelium is covered by the
stratum

comeum

normally

consisting

of

exfoliating

anucleate

keratinocytes.

Histological changes occurring in the skin during lesion development were
documented by microscopic examination of hematoxylin and eosin stained tissue

sections. Normal skin of untreated animals or treated animals with a lesion grade of 0
(Figure 3a) was characterized by a thin anucleate stratum comeum, an epidermal layer

which was composed of 1-2 layers of nucleated keratinocytes and a dermal layer devoid

of cellular infiltrate. The first alterations observed, typical of lesion grade 1 (Figure 3b),
were mild acanthosis (epidermal thickening) to approximately two times that of normal
skin and hyperkeratosis (thickening of the stratum comeum).

In animals with lesion

grades of 2 (Figure 3c), the epidermis had now increased by about three-fold and there

were focal areas of parakeratosis (persistence of nuclei in the stratum comeum). These
animals also exhibited an increase in the dermal layer to twice that of normal animals. A
mild mixed infiltrate of polymorphonuclear and mononuclear leukocytes was observed in
about one-third of the animals. By lesion grade of 3 (Figure 3d), mice continued to

exhibit the epidermal changes already described, in addition to the formation of pustular
crusts in about half of the animals. The mixed dermal infiltrate was now observed in the
majority of the animals. At lesion grade 4 (Figure 3e), histological analysis revealed

55

r

dramatic focal acanthosis (four times that of normal mice), as well as the formation of

ulcers.

A pronounced mixed infiltrate was observed throughout the dermis with

extension into the fat layer. These changes continued to progress to include the entire
shaved area in lesion grades recorded as level 5 (not shown).
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Figure 3
Histopathology of Skn-Directed Autoimmune Skin Lesions
Mice received dorsal shaving on Day -1 and cyclophosphamide immunosuppression 4

hours prior to the administration of Skn immune spleen (SIS) cells on Day 0. Shaved-site
skin was biopsied at various lesion grades and sections stained with hematoxylin and
eosin.

Figures represent characteristic gross lesion appearance as determined from

evaluation of 7-9 tissue sections for each lesion grade. Scale bar, 100 pm.

a) Lesion grade of 0 or in untreated skin: epidermis (E), stratum comeum (SC),
dermis (D), fat (F).

b) Lesion grade of 1: acanthosis (AC), hyperkeratosis (H), dermis (D).
c) At lesion grade of 2: acanthosis (AC), parakeratosis (P), dermis (D),

infiltrate (I).
d) At lesion grade of 3: pustular crusts (PC), acanthosis (AC), parakeratosis (P),
dermis (D), infiltrate (I).

e) At lesion grade of 4: acanthosis (AC), pustular crusts (PC), infiltrate (I),
ulcer (U), dermis (D).
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COTRANSFER OF NORMAL SPLEEN CELLS CONTROLS
AUTOIMMUNE SKIN LESIONS

Previous work with the Skn model of autoimmunity indicated that cotransfer of
normal spleen cells in sufficient numbers controlled lesion development in lesion

forming animals (S.H. Jackman personal communication). To support these findings,
this experiment was repeated. B6AF1 mice were shaved and cyclophosphamide treated as
previously described.

Four hours post-cyclophosphamide treatment, animals were

administered cells as stated below through a tail vein injection. Lesion-forming animals
received adoptive transfer of 50x106 SIS cells. Test animals received similar treatment in

addition to concomitant cotransfer of lOOxlO6 normal spleen cells [or 2XNS cells],
representing a 2:1 ratio of normal B6AF1 spleen cells to SIS cells.

Lesions were

observed daily and graded over a 7 day period. Animals receiving cotransfer of 2XNS
cells demonstrated progressively significant lesion control on Day 5 (p = 0.025), Day 6 (p

= 0.001) and Day 7 (p< 0.001) post-cell transfer when compared to lesion-forming
animals (Figure 4).

As lesion control was a consistent feature in animals receiving

cotransfer of 2XNS cells, these animals are, henceforth, referred to as Tesion-controlling
animals.'
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Figure 4
Cotransfer of B6AF1 Normal Spleen Cells Results
in Lesion Control
B6AF1 mice were shaved, cyclophosphamide pretreated and given either 50x106 SIS
cells (open circle) or 50x106 SIS cells + lOOxlO6 normal spleen (2XNS) cells (closed

circle). Lesions were graded daily over 7 days post-cell transfer. Points represent mean

lesion grade and standard error for that day.

Statistically significant lesion grade

differences between animals receiving SIS cells or SIS cells + 2XNS cells are indicated
by an asterisk (*) for that day.

Data represent 14 SIS animals from 5 different

experiments and 17 SIS + 2XNS animals from 4 different experiments.
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COTRANSFER OF CD4+ ENRICHED NORMAL SPLEEN CELLS
DEMONSTRATES LESION CONTROL

CD4 and CD8* T lymphocytes are known to be important in regulating, as well
as inciting, autoimmune reactions as has been demonstrated in a variety of autoimmune

animal models. In the Skn model of autoimmunity, Figure 4 clearly demonstrated that
the cotransfer of 2XNS cells concomitant with the transfer of pathogenic autoimmune

SIS cells could control skin lesion development. As the phenotype of the regulatory

cell(s) in the 2XNS cell population was not known, negatively selected cell populations
consisting of CD4-depleted-, CD4-enriched-, CD8-depleted

or CD8-enriched normal

spleen cells were cotransferred, in lieu of unfractionated 2XNS cells, at the time of SIS
cell transfer. Prior to cell transfer, flow cytometric analysis was performed to verify that
CD4" or CD8^ cells had been enriched for, or depleted of, the appropriate subset as

required for the designated cotransfer experiment (Figure 5a).

The number of

fractionated spleen cells cotransferred after enrichment or depletion was adjusted

toreflect the approximate number of CD4+ or CD8" cells found in the normal murine

spleen, i.e. 24% and 12%, respectively. This resulted in the cotransfer of either 76x10>6
CD4-depleted-, 24xl06 CD4-enriched-, 88xl06 CD8-depleted, or 12xl06 CD8-enriched
normal spleen cells. Prior to transfer of the appropriate cells, B6AF1 recipients were
shaved and cyclophosphamide treated as previously described. Following cell cotransfer

with SIS cells, the shaved-site was graded for lesion development on Day 7 (Figure 5b).
Animals receiving only SIS cells, i.e. lesion-forming animals, developed
lesions at a mean grade of 3.4 ± 0.9 while animals receiving SIS cells + 2XNS cells, i.e.
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lesion-controlling animals, demonstrated a significantly reduced lesion grade of 1.3 ± 0
.2 (p<0.001) as had been previously observed. When CD4-depleted normal spleen cells

were cotransferred, lesion control was abrogated while lesion control was retained in

animals receiving cells enriched for CD4* lymphocytes (p = 0.003) compared to transfer
of SIS cells alone. These results suggested a regulatory role for CD4~ normal spleen

cells in the control of Skn-directed autoimmune skin lesions. However, this conclusion
was not supported by studies with fractionated CD8+ cells. While cotransfer of CD8-

enriched cells did not result in lesion control, neither did cotransfer of CD8-depleted
cells. Because the CD8-depleted preparation retained CD4^ cells, the presence of this

cell type did not appear to be the only contributing factor for control of lesions.
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Figure 5a

Depletion or Enrichment of CD4+ or CD8+ Cells For Cotransfer
Before and after CD4" or CD8^ depletion or enrichment procedures, spleen cells were
stained with fluorescently labeled antibodies to CD4 and CD8 and analyzed by flow
cytometric analysis. The lower right quadrant indicates the number of cells identified by

the appropriate antibody. The lower left quadrant represents the number of cells not
stained with antibody.
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Figure 5b

Cotransfer of CD4-Enriched Normal Spleen Cells Controls
Skn-Directed Skin Lesions
In preparation for cell cotransfer experiments, all B6AF1 mice were shaved and

cyclophosphamide pretreated. Controls consisted of lesion-forming animals that received

SIS cells (bar 1) and lesion-controlling animals that received SIS cells + unfractionated

2XNS cells (bar 2). In separate experiments, animals received SIS cells in addition to
either CD4-depleted (bar 3), CD4-enriched (bar 4), CD8-depleted (bar 5) or CD8-

enriched (bar 6) normal spleen cells.

Bars represent Day 7 mean lesion grade and

standard error. The asterisk (*) indicates statistically significant differences in lesion
grade as compared to lesion-forming animals (bar 1). n = 16, 16, 5, 5, 8 and 5 for bars 1

through 6, respectively.
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ELEVATED IL-7 mRNA IS ASSOCIATED WITH LESION CONTROL

As cotransfer of lOOxlO6 normal B6AF1 spleen (2XNS) cells resulted in
significantly reduced lesion grades, we asked if selected cytokine levels in the skin were

associated with lesion grade differences observed in lesion-forming and lesion
controlling animals. Cytokines were chosen for their reported contribution to a Th 1 (IL-2,

IL-12p35, IL-12p40, IFN-y) or Th2 (IL-4, IL-10) response, as well as

for

immunosuppressive (TGF-p, IL-10) or hematopoietic (IL-7) activity. B6AF1 mice were

shaved and cyclophosphamide pretreated.

Lesion-forming animals received SIS cell

injection while lesion-controlling animals received concomitant cotransfer of 100 x 106
normal spleen (2XNS). A time course study was performed on skin biopsies collected at
0.5, 1.5,3, and 7 days post-cell transfer. Total RNA was isolated from skin at the shaved

site and mRNA was analyzed using a RT-PCR assay. Figure 6 provides a representative
gel of RT-PCR cytokine products analyzed in these studies while cytokine mRNA skin
levels in lesion-forming- and lesion-controlling animals at specific time points post-cell

transfer are shown in Figures 7a-h.
No significant difference in mRNA level was seen between lesion-forming and

lesion-controlling skin for IL-2 (Figure 7a), IL-4 (Figure 7b), IL-10 (Figure 7d), IL-

I2p35 (Figure 7e), IL-12p40 (Figure 7f), IFN-y (Figure 7g) or TGF-P (Figure 7h). A
particular point of interest was the IL-7 mRNA level (Figure 7c) which was significantly

elevated in lesion-controlling, as compared to lesion-forming animals, on Day 7
suggesting that IL-7 may have a role in promoting the control of lesion development. As

lesion grade was most significantly different between lesion-forming and lesion-

70

controlling skin on Day 7, Figure 8 provides a Day 7 comparison of cytokine mRNA
levels to further demonstrate that only IL-7 mRNA was elevated in lesion-controlling

skin at a time when lesions were actively forming in non-2XNS cell recipients.
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Figure 6
RT-PCR Cytokine Products
Representative agarose gel showing products of PCR amplification after staining with
ethidium bromide.
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Lane 4
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TGF-p (525 bp)
p actin (540 bp)
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Figure 7

Relative Levels of Cytokine mRNA in Lesion-Controlling and
Lesion-Forming Skin
Semiquantitative analysis of cytokine mRNA levels from skin biopsies taken at

0.5, 1.5, 3 or 7 days post-cell transfer was performed by RT-PCR. Animals received
standard pretreatments and transfer of either SIS cells + 2XNS cells, i.e. lesion
controlling animals (closed circle) or SIS cells alone, i.e. lesion-forming animals (open

circle). Results are expressed as relative units of cytokine band net intensity divided by
the band net intensity for the housekeeping gene, p actin, and reported as the mean and
standard error.

The asterisk (*) denotes statistically significant differences between

lesion-forming and lesion-controlling animals for that respective day. Data from lesion

forming skin represents 7 independent experiments with 3 to 5 animals/day for Day 0.5
through Day 3 and 14 animals for Day 7. Data for lesion-controlling skin represents 4
independent experiments with 3 to 4 animals/day for Day 0.5 through Day 3 and 11

animals for Day 7.

Figure 7a:
Figure 7b:
Figure 7c:
Figure 7d:
Figure 7e:
Figure 7f:
Figure 7g:
Figure 7h:

IL-2 mRNA
IL-4 mRNA
IL-7 mRNA
IL-10 mRNA
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IFN-y mRNA
TGF-p mRNA
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Figure 7c
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Figure 8
Day 7 Summary of Relative Cytokine mRNA Expression from

Skin of Lesion-Forming and Lesion-Controlling Animals
Semiquantitative RT-PCR analysis of cytokine mRNA was determined from skin

biopsies taken at Day 7 post-cell transfer. Animals received standard pretreatments and
SIS cells alone, i.e. lesion-forming animals (red bar) or SIS cells + 2XNS cells, i.e.
lesion-controlling animals (black bar). Results are expressed as relative units of cytokine

band net intensity divided by the band net intensity for the housekeeping gene, p actin,
and reported as the mean and standard error.

The asterisk (*) denotes statistically

significant differences between lesion-forming and lesion-controlling animals.

represent

14 and

11

Data

animals from lesion-forming and lesion-controlling skin.

respectively.
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CD4-ENRICHED NORMAL SPLEEN CELL COTRANSFER AND SKIN IL-7
mRNA ARE ASSOCIATED WITH LESION CONTROL
Because elevated IL-7 mRNA expression was associated with lesion control in

2XNS cell recipients, we asked whether similar IL-7 mRNA levels could be
demonstrated in animals that controlled lesion development after receiving cotransfer of
fractionated normal spleen cells.

In these experiments, IL-7 mRNA was observed to be

increased only in the skin of animals receiving cotransfer of CD4-enriched normal spleen
cells as compared to lesion-forming animals (p = 0.003) whereas no statistically
significant difference in IL-7 mRNA was observed in the skin of animals receiving

cotransfer of CD4-depleted, CD8-depleted or CD8-enriched cells (Figure 9a).

This

suggested that lesion control was associated with cotransfer of CD4-enriched normal
spleen cells and an increased expression of IL-7 mRNA in the skin.
While CD4+ normal spleen cells appeared to contribute in regulating th
development of lesions, their presence without some basal level of IL-7 was inadequate

for lesion control.

This is clearly depicted in the composite diagram showing the

relationship among lesion grade, levels of IL-7 expression, and the phenotype of cells

within the cotransferred normal spleen cell population (Figure 9b). In this comparison.
only those recipients receiving cotransfer of 2XNS or CD4-enriched normal spleen cells
demonstrated an elevated IL-7 mRNA and diminished lesion grade as compared to

lesion-forming animals. While CD8-enriched cell cotransfer resulted in a variable IL-7
mRNA level in the skin, lesion control was not observed in the absence of CD4+ cells.
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cotransfer of CD8-depleted cells, which contained CD4+ cells, could not control lesions

without adequate expression of IL-7 mRNA in the skin. Taken together, these findings
suggest that a combination of CD4^ cells and IL-7 mRNA is required to control Skndirected skin lesions in these animals.

EPIDERMAL LOCALIZATION OF IL-7 PROTEIN
Because IL-7 mRNA was significantly elevated in lesion-controlling versus

lesion-forming skin on Day 7, we sought to identify the site of IL-7 expression within the
skin. The location of IL-7 protein was demonstrated by immunohistochemistry. In tissue

displaying an elevated expression of IL-7 mRNA by RT-PCR analysis, protein IL-7 was
observed throughout the epidermis (Figure 10a). The specificity of the reaction was
demonstrated either by staining tissue previously determined to have undetectable levels
of IL-7 mRNA (Figure 10b) or by substituting PBS for the anti-IL-7 antibody (not

shown). Under either of these conditions, IL-7 protein was not detected.
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Figure 9

Association of Cotransfer Condition with IL-7 mRNA Level
and Lesion Grade
a) Day 7 IL-7 mRNA levels were determined by RT-PCR analysis from skin

biopsies taken from animals receiving pretreatment and transfer of SIS cells alone
(bar 1), SIS + 2XNS cells (bar 2), SIS

CD4-depleted normal spleen cells (bar

3), SIS + CD4-enriched normal spleen cells (bar 4), SIS

CD8-depleted normal

spleen cells (bar 5), or SIS + CD8-enriched normal spleen cells (bar 6). Bars
represent mean and standard error for each cotransfer condition. An asterisk (*)

denotes statistically significant differences with respect to lesion-forming skin
(bar 1). n = 16, 14, 5, 5, 8 and 5 for bars 1 - 6, respectively.
b) Relative IL-7 mRNA level and lesion grade at Day 7 post-adoptive transfer were

compared for cell cotransfer recipients. Symbols represent statistically
significant differences with respect to skin IL-7 mRNA levels (*) or lesion grade

(#) when compared to lesion-forming animals (SIS).
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Figure 10
IL-7 Is Expressed In the Epidermis
Tissue from skin previously determined to exhibit elevated (a) or negative (b) levels

of IL-7 mRNA were subjected to immunohistochemical staining for IL-7 protein.
Stain specific for IL-7 was shown in the epidermis (E) as a brown reaction product.
The tissue was counterstained with hematoxylin. Tissue from the same skin in (a) did

not stain when PBS was used in place of the anti-IL-7 antibody. Scale bar, 100 pm.
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Figure 10a

Figure 10b
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IL-7 CULTURE OF NORMAL SPLEEN CELLS DOES NOT

ENHANCE LESION CONTROL
Other investigators (Herbelin et al., 1998) have observed that culture of T lymphocytes

containing a source of regulatory cells in IL-7 enhances protection from disease induced
by cotransfer of autoreactive cells. In these experiments, cotransfer of as few as 5xl06

IL-7 cultured cells was shown to prevent disease transfer (Herbelin et al., 1998). With
respect to the Skn model of autoimmunity, we asked if the regulatory ability of

unfractionated 2XNS cells or CD4-enriched spleen cells might also be enhanced by in

vitro culture in the presence of rIL-7 prior to cell transfer.

To determine an optimal

concentration of murine rIL-7, 20x106 normal spleen cells were cultured in rIL-7 varying
concentrations from 338 -1670 U/ml. Following a 60 hr incubation, cell viability was
assessed (Figure Ila).

Results demonstrated that normal spleen cell viability was

maximal when 1000 U/ml rIL-7 was added to the growth medium and that this
corresponded to the concentration of IL-7 used for potentiation as previously described

(Herbelin et al., 1998). Therefore, unfractionated or CD4-enriched normal spleen cells
were cultured in 1000 U/ml rIL-7 for 60 hr and the number of cells used for cotransfer
was adjusted to approximate those shown to be effective in other autoimmune murine

models (Herbelin et al., 1998).
B6AF1 mice were shaved and cyclophosphamide pretreated. At Day 0, mice

received 50x106 SIS cells in addition to 2xl06 or 16xl06 rIL-7 treated unfractionated

normal spleen cells (Figure lib) or 2xl06, 7xl06 or 24xl06 rIL-7 treated CD4-enriched
normal spleen cells (Figure 11c). Lesions were graded on Day 7. Cotransfer of 2xl06 or
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16xl06 IL-7 cultured unfractionated normal spleen cells exhibited no lesion control
thereby demonstrating no enhanced regulatory effect of IL-7 culture on these cells prior

to cell transfer. Similarly, transfer of 2x106 or 24x106 IL-7 cultured CD4-enriched cells
demonstrated no lesion control (Figure 11c). While transfer of 7x106 IL-7 cultured CD4enriched cells showed some lesion control (p = 0.011; Figure 11c, bar 4) as compared to

lesion-forming animals, these animals did not exhibit similar lesion-controlling ability as

compared with non-IL-7 cultured CD4-enriched cell recipients (p<0.001; Figure 11c, bar
2).

Taken together, an enhanced regulatory effect could not be documented when cells

with known regulatory ability were cultured in rIL-7 prior to transfer. In fact, animals

generally displayed a compromised ability to control lesions. This was most clearly seen

when similar numbers of noncultured (Figure 11c, bar 2) or IL-7 cultured (Figure 11c,
bar 5) CD4-enriched cells were compared.

As culture in rIL-7 had no enhanced effect on the ability to control lesions, we
sought to document cell surface changes occurring in IL-7 cultured cells that may have
adversely affected their lesion regulating activity upon cotransfer. Cell surface markers

were stained with fluorescence-labeled antibodies for flow cytometric analysis prior to

and following in vitro culture in rIL-7. We found that the percentage of cells expressing
CD3, CD4, or CD8 was increased (21%, 28%, or 45%, respectively) for unfractionated

(Figure lid) and CD4-enriched (1%, 3%, or 20%, respectively) (Figure lie) normal

spleen cells. However, a negative effect was observed in the expression of the IL-7R

(CD 127). In both instances, unfractionated and CD4-enriched normal spleen cells after

culture in rIL-7 demonstrated a downregulated expression of IL-7R (-21% and -36%,
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respectively) which most likely compromised their ability to respond to IL-7 in vivo and.

therefore, to participate fully in IL-7-associated lesion control when transferred.
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Figure 11

In Vitro IL-7 Culture of Normal Spleen Cells for Cotransfer
a) B6AF1 normal spleen cells at a concentration of 20x106 cells/ml were cultured in
varying concentrations of rIL-7.

Points represent viable cells remaining

following a 60 hr incubation.
b) Pretreated B6AF1 mice were administered SIS cells (bar 1), SIS + 2XNS (bar 2)

or SIS + 2xl06 (bar 3) or 16xl06 (bar 4) IL-7 cultured unfractionated normal

spleen cells. Bars represent Day 7 mean lesion grade and standard error for the
respective cotransfer condition.

The asterisk (*) denotes statistically significant

differences as compared to lesion-forming animals (bar 1). n

4, 3, 3, and 3 for

bars 1 through 4, respectively.
c) Pretreated animals were administered

SIS (bar 1), SIS + 24x106 non-IL-7

cultured CD4-enriched cells (bar 2), or SIS + 2xl06 (bar 3), 7xl06 (bar 4) or

24x106 (bar 5) IL-7 cultured CD4-enriched normal spleen cells. Bars represent
Day 7 mean lesion grade and standard error. The asterisk (*) denotes statistically
significant differences in lesion grade as compared to lesion-forming animals (bar

1). n = 4, 5, 4, 3, and 3 for bars 1 through 5, respectively.

d,e) Prior to and following in vitro culture in rIL-7, unfractionated (d) or CD4enriched (e) normal spleen cells were independently stained with FITC- or PElabeled antibodies to CD3, CD4, CD8, or CD 127 (IL-7R) for cell surface
characterization by one color flow cytometric analysis.
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FIGURE 11e
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CLONING OF IL-7 cDNA INTO A MAMMALIAN EXPRESSION PLASMID

FOR USE IN A TOPICAL SOMATIC GENE THERAPY

Because elevated levels of IL-7 were clearly associated with lesion control, we

asked whether exogenous IL-7 expression within the skin of lesion-forming animals

could control lesion development. The pCMV-Tag 1 vector was selected for use in
subsequent somatic gene therapy trials. Murine IL-7 cDNA in a BlueScript KS +/- vector
was amplified by PCR to create restriction sites for subcloning into the Stratagene

pCMV-Tagl mammalian expression vector.

The pCMV-Tagl vector was chosen

because the expression product of the IL-7 target gene could be tagged with the N-

terminus

FLAG

epitope (Figure

endogenously-produced IL-7.

12)

to

differentiate

plasmid-generated

from

A plasmid control consisted of the Stratagene pCMV-

Tagl vector containing a firefly luciferase gene associated with a FLAG sequence for Nterminus epitope tagging (Figure 12). The pCMV-Tagl plasmid containing the IL-7
cDNA sequence was referred to as ‘plasmid-IL-7’.
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Figure 12
2

Cytomegalovirus Promoter-Driven Plasmid Expressing a

FLAG-IL-7 Fusion Construct
Plasmid map of the IL-7 or firefly luciferase vector indicates the gene insertion site
and the FLAG epitope tag.
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PLASMID-IL7 PRODUCT EXHIBITS BIOLOGICAL ACTIVITY THROUGH

EXPANSION OF AN IL-7-DEPENDENT CELL LINE

To demonstrate the biological activity of the plasmid-IL-7 construct, we first

determined if the pCMV-Tag vector could be transfected into mouse C2 muscle cells. C2
cells were transfected with pCMV-Tag vector containing the luciferase reporter gene.
Forty-eight hours later, the cells were lysed and a luciferase assay performed. As seen in

Figure 13a, transfection had occurred as reporter gene activity was detected in the C2 cell

lysate.
C2 cells were then transfected with plasmid-IL-7.

Forty-eight hours post

transfection, cell supernatant fluid was removed and incrementally added to the IL-7-free

growth medium of an IL-7-dependent immature B lymphocyte cell line designated 2E8.
Independently, 0 - 24 pl of plasmid-transfected C2 cell supernatant was added to cultures
containing 5xl05 IL-7-dependent 2E8 cells/ml. Following a 48 hr incubation, addition of

21 pl of supernatant from plasmid-transfected C2 cells was shown to maximally expand
the 2E8 cells (Figure 13b). As IL-7 concentration was not determined in the plasmid-

transfected C2 cell supernatant, an IL-7 dependent growth curve was performed on 2E8
cells to determine the optimal concentration required for 2E8 cell expansion (Figure 13c).
While 5xl05/ml 2E8 cells were expanded when 21 pl of transfected C2 cell supernatant
was added, the growth curve demonstrated that 5xl05/ml 2E8 cells could be expanded in

2-4 ng/ml of murine rIL-7.

105

Figure 13

Bioactivity of pCMV-Tagl-IL-7 Product
a)

C2 cells were transfected with pCMV-Tag vector containing a luciferase reporter
gene. After 48 hr incubation of culture, cells were lysed and the lysate tested for

luciferase activity using a standard luciferase assay. The asterisk (*) represents the
lysate reading as compared to a firefly luciferase standard curve.
b)

Bioactivity of the pIasmid-IL-7 product was tested by adding culture supernatant in
the amount of 0-24 pl from plasmid-IL-7-transfected C2 cells to IL-7-free 2E8 cell

culture medium containing 5xl05 2E8 cells/ml. Points represent pl of plasmid-IL-7
C2 cell supernatant added to the culture medium and viable 2E8 cells/ml observed

following a 48 hr incubation period.
c)

The concentration of IL-7 required to expand 5xl05 2E8 cells/ml in culture was

determined by culturing 2E8 cells in varying amounts of rIL-7 in a concentration
range of 0-8 ng rIL-7/ml. Points represent the concentration of IL-7 contained in the

growth medium/ml and viable 2E8 cells/ml observed following a 48 hr incubation.

106

Figure 13a
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Figure 13b
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‘A’ AND ‘B’ SITES DEFINED

i

After demonstrating biologically active IL-7 as a product of in vitro cell

3

transfection with plasmid-IL-7, we proceeded with in vivo transfection of the skin of
B6AF1 mice.

Because control of autoimmune skin lesions by topical somatic gene

therapy had not been reported. Therefore, the site of plasmid application was chosen

based on certain expectations such as low level transfection efficiency (Prud’homme et
al., 2001) and localized, transient plasmid expression (Yu et al., 1999).

As lesion

forming animals would be used in these experiments, lesions could be predicted to be

distributed over the entire shaved site area by Day 7. Also, given some degree of inter
animal variability could be expected among lesion-forming animals, we elected to

transfect only a portion of the shaved site allowing the untreated portion to act as an in
vivo internal lesion-forming control. To do this, experiments were designed in which the

righthand portion of the shaved site, designated the ‘A’ site, was used as the plasmid

application site while the lefthand portion of the shaved site, designated the ‘B’ site, was
not treated with plasmid (Figure 14).

By applying plasmid at the ‘A’ site, we surmised

that transient transfection of the skin and subsequent IL-7 expression would be generally
restricted to the site of transfection at the ‘A’ site where potential lesion-controlling
effects could be observed and compared to the untreated ‘B’ site where lesions would

form.
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Figure 14
‘A’ and ‘B’ Sites Defined
B6AF1 mice were shaved as previously described on Day -1. The right half of the
shaved site was designated the ‘A’ site while the left half was designated the ‘B’ site.
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Figure 14
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pCMV-LUCIFERASE CONTROL PLASMID TRANSFECTS MURINE SKIN
The murine skin transfection method of Yu et al (1999) was used which

consisted of shaving followed by brushing the ‘A’ site with a child’s toothbrush for 100

strokes. Following this procedure, control plasmid (pCMV-Luciferase) was applied in an
amount of 20pg DNA to the ‘A’ shaved site of a normal animal. The following day, skin
was removed and analyzed for the presence of luciferase using a standard luciferase

assay. A low level luciferase transfection product was detected in the skin sample (data

not shown) which provided evidence that murine skin could successfully be transfected
with pCMV-Tagl vector using this topical application procedure.

PLASMID-IL-7 APPLICATION TO NORMAL SKIN DOES NOT CAUSE
LESIONS
Previous studies of transgenic mice indicate that overexpression of IL-7 in the

skin results in the development of lesions (Rich et al., 1993). Although the level of IL-7

in the skin of these transgenic animals was not reported, we asked whether plasmid-IL-7
expression in the skin of normal mice would result in the development of skin lesions.

To determine this, B6AF1 mice were shaved at both the ‘A’ and ‘B’ sites at Day -1. No
cyclosphosphamide or SIS cells were administered. The ‘A’ site was brushed and

concentrations of plasmid of 0, 1, 2.5, 5, 10 or 20 pg were applied to the central portion
of the ‘A’ site on Day 0. Animals were observed for lesion development over a 7 day

period at the shaved site and lesions graded on Day 7. We observed no lesions at either

113

the kA’ or ‘B’ sites at any of the plasmid concentrations evaluated (data not shown)

indicating that topical application of up to 20 pg of plasmid-IL-7 did not induce skin
pathology per se.

ADJACENT ‘A SITE’ LESION GRADE IMPROVEMENT WITH APPLICATION
OF PLASMID-IL-7

Yu et al. (1999) demonstrated effective transfection of murine skin with a topical

application of 20 pg of plasmid DNA. We selected similar amounts for our preliminary
trials. To determine the lesion-controlling effect of topical plasmid-IL-7 application in

the skin of lesion-forming animals, animals were shaved at the ‘A’ and ‘B’ sites and

cyclophosphamide pretreated followed by injection of SIS cells at Day 0. Immediately

following SIS cell transfer, each animal was brushed and either 10 or 20 pg of plasmid-

IL-7 or 20 pg plasmid control was applied to the ‘A’ site. Lesion scores were recorded at

both the ‘A’ and ‘B’ sites at Day 7 (Figure 15). Application of plasmid without IL-7 had
no effect on lesion control as lesions formed in these recipients at both ‘A’ and ‘B’ sites.
Opposite to what was expected, in mice where plasmid-IL-7 was applied to the ‘A’ site,

the ‘A’ site developed lesions at similar severity as observed in recipients of the control
plasmid, while the ‘B’ site was protected from lesion formation. Comparable results were

observed when 10 pg or 20 pg of plasmid-IL-7 was applied. Based on the effect of
overexpression of IL-7 in transgenic mice (Rich et al., 1993), these unexpected findings

suggested that the concentration of plasmid-generated-IL-7 at the ‘A’ site might be
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excessively high and therefore ineffective in lesion control while the ‘B’ site was at a

sufficient distance so as to provide a lower concentration of IL-7 via a dilution effect
resulting in lesion control. This led us to examine lowering the dosage of plasmid IL-7 at

the ‘A’ site. With application of 2.5, 5, 10 or 20pg of plasmid-IL-7 we again observed
lesion control at the ‘B’ site but not the ‘A’ site (Figure 16a, 16b), while administration of

Ipg of plasmid-IL-7 demonstrated no lesion control at either site. Overall, the results
supported the presumption that lesion-control at the ‘B’ site was influenced by the
concentration of plasmid-IL-7 applied to the ‘A’ site, that lesion control could be retained

over a range of plasmid-IL-7 doses, and that the optimal plasmid-IL-7 dosage was

between 1-2.5 pg of DNA. Our finding that lesion control was not observed at the 4A’
site suggested that some other factor(s) was modifying the ability to control lesions at the

‘A’ site for which brushing was a candidate. While brushing the shaved site had not been

shown to be detrimental in normal mice (data not shown), we could not rule out the
detrimental effect of brushing on the reactive site in lesion-forming animals.
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Figure 15
‘A’ Site Plasmid-IL-7 Application Controls ‘B’ Site Lesions
B6AF1 mice were shaved at Day -1 then cyclophosphamide pretreated and injected with

SIS cells at Day 0. Immediately following cell administration, shaved skin was brushed
at the ‘A’ site. Twenty pg of control plasmid or plasmid IL-7 at concentrations of 10 pg

or 20 pg was applied. ‘A’ and ‘B’ sites were assessed for lesion grade at Day 7.
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Figure 16

Effect of Varying ‘A’ Site Plasmid Concentrations
B6AF1 mice were shaved at Day -1 then cyclophosphamide pretreated and injected with

SIS cells at Day 0. Immediately following cell administration, shaved skin was brushed
at the ‘A’ site and plasmid control or plasmid-IL-7 at varying concentrations was applied.

Skin at both the ‘A’ and ‘B’ sites was assessed for lesion grade on Day 7. Figure 16a
represents combined data from 2 experiments.

representative animals is provided in Figure 16b.
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‘CDE’ SITE CLIPPING, BRUSHING AND

DAILY PLASMID APPLICATION CONTROLS LESIONS
The finding that application of plasmid-IL-7 at the ‘A site’ was unsuccessful in

controlling ‘A site’ lesions while successful in controlling ‘B site’ lesions, suggested a

potential detrimental brushing effect on ‘A site’ lesion development.

To avoid ‘A site’

brushing, we examined the effect of plasmid-IL-7 application on sites adjacent to the ‘A
site’. As shaving is an impetus for lesion production in the Skn model of autoimmunity,

we chose to clip the fur using Oster animal clippers at adjacent areas to the ‘A’ site as
clipping of the fur circumvents lesion development in this model (Jackman, S.H. personal
communication). Therefore, adjacent sites, called ‘C’, ‘D’, and ‘E’, which flanked the
‘A’ site to the north, east and south, were selected as sites of plasmid application (Figure

17). As plasmid-IL-7 would be applied to sites remote to the A site and even more
remote to the B site, daily application of 5 pg of plasmid was chosen to be applied to
each site. As we had observed that neither control plasmid nor buffer alone contributed

to lesion development, buffer was selected as the control application in the following
experiments (data not shown).

Only lesion-forming animals were used in these

experiments. Animals received shaving of the ‘A’ and ‘B’ and clipping of the ‘CDE’
sites on Day -1 followed by cyclophosphamide treatment 4 h prior to the administration

of SIS cells on Day 0. Immediately following SIS cell administration, ‘CDE’ sites were

brushed and 5 pg plasmid-IL-7 or buffer was applied daily through Day 6. Lesions were
graded on Day 7 at the ‘A’ and ‘B’ sites.

Plasmid IL-7 recipients demonstrated a

significant reduction in both ‘A’ and ‘B’ site lesion grade (Figure 18a; 18b upper and
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center panel) as compared to non-plasmid recipients (Figure 18a; 18b lower panel). The

microscopic changes at the “A” and “B” sites also appeared to correlate with the clinical
improvement of the individual skin lesions.

Mice receiving plasmid-IL-7 showed

alterations characteristic of lesion grade 1 with focal hyperkeratosis and parakeratosis
(Figure 18c, upper panel). The plasmid application “CDE” sites of these mice resembled

skin of lesion grade 0.

In contrast, the “A” and “B” sites of non-plasmid recipients

demonstrated an acanthotic epidermis of 3-4 times that of normal skin with parakeratosis

and pustular crusts.

The dermis was also thickened and most mice had the mixed

inflammatory infiltrate equivalent to lesion grade 3 (Figure 18c, lower panel). With the

exception of some mice at the ‘C’ site only, the ‘CDE’ sites of the non-plasmid mice
were equivalent to lesion grade of 0 or 1.
In addition, application of plasmid-IL-7 showed lesion control (p = 0.006) similar
to that observed in animals receiving cotransfer of 2XNS (p <0.001) or CD4-enriched

normal spleen cells (p

0.003) when compared to lesion-forming animals (Figure 19).

Taken together, these findings demonstrated that topical somatic gene therapy employing
plasmid-IL-7 produced lesion control without the need for cell cotransfer, could be
applied at sites adjacent to the area of lesion formation, and facilitated lesion control as

effectively as was observed with the cotransfer of 2XNS or CD4-enriched cells.
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Figure 17

‘CDE’ Site Defined
B6AF1 mice were shaved at the ‘A’ and ‘B’ sites as previously described. Flanking the

‘A’ site to the north, east and south, areas of approximately 3 cm2 area were clipped using
Oster animal clippers. The clipped area to the north of the ‘A’ site was designated the

‘C’ site, to the east was designated the ‘D’ site and to the south was designated the ‘E’

site for purposes of plasmid application.
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Figure 17
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Figure 18
PIasmid-IL-7 Controls Lesions at the ‘A’ and ‘B’ Sites
B6AF1 mice were shaved at the ‘A’ and ‘B’ sites as previously described on Day -1. In

addition to shaving, fur was clipped at the ‘CDE’ sites.

Animals were given

cyclophosphamide 4 hr prior to the administration of SIS cells on Day 0. Immediately
following the administration of cells and daily thereafter for 6 days, the ‘CDE’ sites were

brushed and 5 pg of plasmid-IL-7 or buffer containing no plasmid was applied. Lesions
were graded on Day 7. Figure 18a data represents ‘A’ and ‘B’ site lesion grades for
animals receiving plasmid (n = 5) and for animals receiving no plasmid (n

represent mean lesion grade and standard error at Day 7.

4). Bars

The asterisk (*) denotes

statistical significance in lesions of plasmid-IL-7 as compared to no plasmid recipients.
Representative gross lesions from plasmid-IL-7 recipients (Figure 18b; n = 5) or non

plasmid recipients (Figure 18c; n = 4) are provided.
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Figure 18b
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Figure 18c
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Figure 19
Comparison of Lesion Control for 2XNS Cell, CD4-Enriched

Cell or Plasmid-IL-7 Recipients
Day 7 lesion grade comparison of lesion-forming animals (bar 1) with animals having
received either 2XNS cells (bar 2) or CD4-enriched normal spleen cells (bar 3) as a

cotransfer inoculum, or by daily ‘CDE’ site application of 5 pg of plasmid-IL-7 (bar 4).
Bars represent mean lesion grade and standard error for the respective treatment. The

asterisk (*) denotes statistically significant differences as compared to lesion-forming
animals, n = 16, 16, 5, or 5 for bars 1 through 4, respectively.
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€CDE’ SITE PLASMID APPLICATION RESULTS IN ‘A’ AND ‘B’ SITE

DETECTION OF FLAG-IL-7 mRNA
As the effect of plasmid-IL-7 application was observed at a site remote to the
place of application, we sought to demonstrate that the plasmid-IL-7 gene product was

present at the site of observed lesion control. On Day 7 ‘A’ and ‘B’ site tissue biopsies

were taken from plasmid-IL-7 or no-plasmid recipients and analyzed using RT-PCR for

detection of the FLAG-IL-7 mRNA fusion product. In plasmid recipients demonstrating

lesion control, FLAG-IL-7 mRNA was detected in all ‘A’ and ‘B’ site skin biopsies
whereas neither lesion control nor FLAG-IL-7 mRNA was detected in non-plasmid
recipients (Figure 20). These findings demonstrated that plasmid-IL-7 expression at the
site of lesion formation contributed to lesion control and that plasmid-generated-IL-7 was

detectable at a site remote to the site of application.

PLASMID-IL-7 MEDIATED LESION CONTROL IS INDEPENDENT OF AND

ACTS TO REDUCE ENDOGENOUSLY EXPRESSED IL-7

Skin biopsies from plasmid-IL-7 recipients were analyzed by RT-PCR for FLAGIL-7 and endogenously expressed IL-7 mRNA (Figure 21; Appendix A). In the skin of

plasmid IL-7 recipients exogenous FLAG-IL-7 mRNA was readily detected while
endogenous IL-7 messages were not observed.

This suggested that plasmid-IL-7,

independent of endogenous IL-7 mRNA, was responsible for lesion control.
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It also

I

suggested that that a mechanism exists in the skin to regulate IL-7 levels and that this

regulatory mechanism was responsive to exogenously supplied IL-7.

PLASMID-IL-7 MEDIATED LESION CONTROL IS INDEPENDENT OF AND

DOES NOT ALTER OTHER CYTOKINE mRNA LEVELS IN THE SKIN
To determine if other cytokine levels were altered due to the expression of

plasmid-IL-7, Day 7 skin biopsies taken from the ‘A’ site were evaluated for IL-2, IL-4,
IL-10, IFN-y and TGF-£ mRNA (Figure 22).

No differences were found for these

cytokines in plasmid-IL-7 as compared to non-plasmid-IL-7 recipients. Overall, the data
suggested that plasmid-IL-7 associated lesion control was most likely acting independent
of other cytokines.
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Figure 20

Day 7 Skin Comparison of FLAG-IL-7 mRNA Level and

Lesion Grade in Plasmid And Non-Plasmid Recipients
I

Skin biopsies taken from the ‘A’ and ‘B’ sites of lesion-forming animals having received
daily C, D and E site application of 5 pg of plasmid-IL-7 at each site or buffer were
analyzed for FLAG-IL-7 mRNA using a RT-PCR assay and compared to lesion grade. To

)

nullify each tissue sample for the presence of plasmid, two RT reactions were performed,

one containing reverse transcriptase (‘RT positive’) and the other where no reverse
transcriptase was added (‘RT minus’). Following PCR, net intensity of the ‘RT minus’

band was subtracted from the ‘RT positive’ band. The remainder was then divided by the
net intensity of the [3 actin band to derive a relative value for FLAG-IL-7 mRNA. Points
represent mean and standard error for that group.

Asterisk (*) denotes statistical

significance between the two groups with respect to lesion grade. The pound sign (#)
denotes statistical significance with respect to the FLAG-IL-7 mRNA level, n = 5 for

each group.
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Figure 21
■

-

Lesion Site Endogenous IL-7 or Plasmid-IL-7 mRNA Level In
I

Plasmid-IL-7 Recipients
Skin biopsies taken from ‘A’ or ‘B’ site of recipients prepared as lesion-forming animals
having received daily ‘CDE’ site application of 5 pg of plasmid-IL-7 were analyzed for

endogenously produced IL-7 (black bar) and exogenously supplied FLAG-IL-7 (red bar)
mRNA using a RT-PCR assay. To nullify each tissue sample for the presence of plasmid,

two RT reactions were performed, one containing reverse transcriptase (‘RT positive”
and the other where no reverse transcriptase was added (‘RT minus’). Following PCR,
net intensity of the ‘RT minus’ band was subtracted from the ‘RT positive’ band. The

remainder was then divided by the net intensity of the P actin band to derive a relative

value for FLAG-IL-7 mRNA. Bars represent mean and standard error for Day 7 IL-7
mRNA. n = 4.

135

Figure 21

1.0
0.9 0.8 -

c
o
cn

0.7 0.6 -

0.5 -

Z
0<

E

0.4 -

0.3 -

0.2 0.1 0.0

Exogenous
FLAG-IL-7

Endogenous
IL-7

136

r

Figure 22
Day 7 Cytokine mRNA Level in Plasmid-IL-7 or Non-Plasmid
Recipient Skin
Biopsies from the ‘A’ site skin of lesion-forming animals having received daily ‘CDE’

site plasmid-IL-7 application (black bar; n = 9) or no plasmid, i.e. buffer only (red bar; n
= 4) for cytokine mRNA analysis using an RT-PCR assay. Data represents skin biopsies
taken from animals in 3 different experiments. Bars represent mean and standard error

for that respective cytokine mRNA relative to p actin.
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Figure 22
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DISCUSSION
Autoimmunity is the response of the immune system against constituents of the
host’s own tissues which when directed to antigens confined to a particular organ
characterize the ‘organ-specific’ autoimmune diseases.

While the etiology of these

diseases remains obscure, evidence is accumulating that T cells play a key role in the
development of organ-specific autoimmune diseases in humans and animals (Van Parijs

et al., 1998). Current research has focused on identifying the role that immunologic,

environmental and genetic factors play in the generation, activation, expansion and

control of self-reactive T cells. Animal models have provided the means to study the
etiology of autoimmunity and are based on thymic production of pathogenic, self-reactive
T cells, antigen-induced activation of self-reactive T cells or impaired control of self-

reactive T cells (Sakaguchi, 2000).

Under normal conditions, mechanisms of self-tolerance protect the host against
potentially self-reactive lymphocytes. Clonal deletion is a well recognized mechanism of

self-tolerance whereby T cells reactive with self-antigens expressed in the thymus are
deleted.

However, the mechanisms of peripheral tolerance to self-antigens expressed

extrathymically, e.g. skin, are less well understood. Two general peripheral tolerance
mechanisms have been proposed, one involving the functional inactivation of
autoreactive T cells, i.e. T cell clonal anergy, and the other involving an active process of

suppression whereby T cells are prevented from displaying their autoreactive potential by

other antagonizing T cells (Fowell et al., 1993). At present, the repertoire of regulatory T

cells capable of modulating peripheral autoimmune reactivity, their requirements for
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activation, their cellular targets and their molecular basis for protection are poorly
understood (Liblau et al., 1995). While tissue-specific factors may also play a

fundamental role in the development and control of organ-specific autoimmunity, little is

known about the mechanism(s) by which regulation of autoreactive CD4^ T cells occurs

in the skin.
The Skn model of autoimmunity is an excellent model for studying

autoimmune regulation as 1) the epidermal target, i.e murine Skn antigens, has been

identified (Boyse et al., 1968; Boyse et al., 1970), 2) it represents a CD4" T cell induced
phenomenon, 3) it is expressed in the skin which can be easily monitored and biopsied,

and 4) it can be induced in non-genetically modified animals. Erythema, hyperkeratosis,

pustules and ulceration characterize the gross skin lesions that form in the Skn model

Histopathology is associated with keratinocyte hyperproliferation with hyper- and
parakeratotic differentiation, epidermal influx of polymorphic leukocytes into pustules,

and the presence of a mono- and polymorphic infiltrate in the dermis that extended into
the fat layer of the skin.

Both gross and histologic features of the Skn model of

autoimmunity have overlapping features observed in other skin-based autoimmune
diseases (Bos et al., 1999).
Cyclophosphamide, the immunosuppressive agent used in these studies, is one of
the ‘standard’ protocols for the selective depletion of suppressor T cell function in vivo

(Yasunami et al., 1988; Barrett et al., 1995). Cyclophosphamide has also been used in

other animal models to provoke autoimmune disease including diabetes in the NOD
mouse (Yasunami et al., 1988) and experimental allergic encephalomyelitis (Kardys et
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al., 1981; McKenna et al., 1984; Miyazaki et al., 1985), as well to mediate tumor

regression (Awwad et al., 1989). In our model, we demonstrated that three events were
necessary to elicit autoimmune lesion progression, namely, i) mild traumatization of the

skin by shaving,

ii) cyclophosphamide immunosuppression, and iii) systemic

administration of Skn-immune spleen [SIS] cells. A growing body of evidence supports

the presence of peripheral self-reactive T cells circulating in humans and animals while
remaining free of autoimmune disease (Goverman et al., 1993). We also observed this
phenomenon in which administration of SIS cells without shaving or immunosuppression

did not result in autoimmune consequences in these animals. Only when mice were

shaved and cyclophosphamide treated prior to the administration of SIS cells did lesions

form in a predictable, shaved-site-restricted and progressive fashion over a 7 day period

and, henceforth, were referred to as ‘lesion-forming animals’.
Our speculation that Skn autoimmune lesions resulted from cyclophosphamide

induced T suppressor cell (T regulatory or Tr cell) depletion and/or inactivation and

subsequent deregulation of self-reactive SIS cells, was supported by unfractionated

spleen cell replacement experiments. These demonstrated that cotransfer of normal
syngeneic spleen [2XNS] cells in adequate numbers resulted in significantly diminishing

lesion severity in our animals. As pretreated animals receiving cotransfer of 2XNS + SIS
cells consistently controlled their lesions, they were designated Tesion-controlling
animals’. Cotransfer studies in other autoimmune models have also demonstrated that

disease progression can be controlled by restoring the presumptive regulatory cells as the
transfusion of mononuclear cells from nondiabetic NOD mice prevents spontaneous
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cyclophosphamide-induced diabetes (Charlton et al., 1989) while cotransfer of

thymocytes, as well as spleen CD4" cells, efficiently provides protection from IDDM

disease development (Boitard et al., 1989).
As the phenotype of the regulatory cell(s) within the normal unfractionated spleen

cell population was not known, we performed CD4* or CD8+ enrichment and depletion

studies that identified a CD4* T cell as the cell essential for lesion control. In our model

system, cotransfer of SIS + CD4-enriched normal spleen cells controlled lesion severity
while control was abrogated by cotransfer of SIS cells + CD4-depleted normal spleen

cells. This was in keeping with other reports identifying a regulatory role for CD4" T
cells in autoimmune disease (Arthur et al., 1986; Birkeland et al., 1988; Lee et al., 1990;
Powrie et al., 1990; Fowell et al., 1991; McKnight et al., 1991; Fowell et al., 1993;
Powrie et al., 1993; Powrie et al., 1994). We observed that cotransfer of SIS + CD8-

enriched did not result in lesion control suggesting that CD8+ cells alone were insufficient

in mediating lesion control in the Skn model of autoimmunity.

Interestingly, we

observed no lesion control with the cotransfer CD8-depleted normal spleen cells that
contained an adequate number of CD4" T cells for lesion control. We could not rule out
that CD4^ cells themselves might be regulated by a third population that in turn were held

in check by CD8+ cells. While the regulatory cell cascade is not known, CD4-enrichment
and depletion studies indicated that CD4' cells were necessary for lesion control while
CD8-enrichment experiments indicated that CD8* cells alone were not sufficient in

mediating this effect.
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One approach for elucidating the mechanism(s) of self-reactive T cell control is to
study the effect of immunomodulatory proteins, such as cytokines, on autoimmune

disease pathogenesis. As organ-specific autoimmune diseases are often characterized by
a Thl cell-mediated immune response, it is thought that the balance of antigen-specific

Thl/Th2 cells may be key to the clinical outcome.

While factors that define the

environment conducive for differentiation of CD4" T cells into Thl versus Th2 cells are

not completely understood (Nicholson et al., 1996), it has been shown that by modulating
the Thl/Th2 immune response that it is possible to regulate the development of clinical

autoimmune disease (Falcone et al., 1999a). For example, in the NOD mouse model of
diabetes, injection of CD4+ transgenic T cells specific for a pancreatic autoantigen which

had differentiated in the presence of Thl cytokines in vitro causes disease, yet injection
of cells with the Th2 phenotype, while expressing the same antigenic specificity, does not

(Katz et al., 1995). Furthermore, it is readily accepted that the cytokine-secreting profiles

of Thl and Th2 cells are also strong cross-inhibitors of the opposite cell type with Thlassociated cytokines such as IFN-y promoting autoimmune disease development (Kalden

et al., 1998); De Maeyer, 1998) and Th-2 associated cytokines such as IL-4 promoting
downregulated immune responses (Chang et al., 1999; Piccirillo et al., 1999).

In a 7 day time course study of biopsies taken from lesion-forming and lesion

controlling skin, we did not observe differences in Th2 (IL-4, IL-10), Thl (IL-2, IL-12,
IFN-y) or immunosuppressive Th3 (TGF-P, IL-10) cytokines at any time point analyzed
and therefore we could not provide evidence for an altered level of these cytokines in
lesion-controlling animals.

This was in contrast to numerous reports that cytokines
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belonging to the Th2 pathway directly downmodulated Thl autoimmune responses
(Falcone et al., 1999a). However, not all models support this general finding (Pankewycz
et al., 1992; Chen et al., 1994; Wogensen et al., 1994; Akhtar et al., 1995; Han et al.,

1996; Bridoux et al., 1997; Groux et al., 1997; Zekzer et al., 1997). Recently a regulatory
cell subset, CD4+ CD45RBl0W CD38* T cells, was shown to inhibit both T cell activation

and secretion of effector cytokines in vitro by a mechanism independent of TGF-P and
IL-10 (Read et al., 1998). Another regulatory subset, CD4^CD62L" T cells, was shown

to produce very low levels of IL-2 and IFN-y and no IL-4 and IL-10 upon stimulation in

vitro while anti-cytokine antibody treatment of mice showed that the protection afforded
by spleen CD62L+ T cells was not mediated by IL-4 or IL-10, hence distinct from a Th2

or a Th3 (Trl)-type response (Takahashi et al., 1998).

While our studies targeted the

skin, it is feasible that SIS cells were being controlled at another location, e.g. in the

systemic circulation or skin-draining lymph nodes. However, it was also conceivable that

other factor(s), rather than a Th2 or Th3 (Tri) cytokine environment, were contributing to
lesion control.

In a comparison of lesion-forming and lesion-controlling skin on Day 7, when
lesion grade was observed to be significantly different for these two test populations, only

IL-7 mRNA was observed to be elevated in lesion-controlling skin suggesting a role for
IL-7 in lesion control.

Enrichment and depletion studies further identified IL-7 as

elevated in the skin of lesion controlling CD4-enriched cell recipients whereas non-lesion

controlling animals were observed to express a decreased skin level IL-7 mRNA.

Therefore, taken together with our earlier findings, autoimmune skin lesions could be
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controlled with cotransfer of 2XNS cells or CD4-enriched normal spleen cells, both of

which were associated with increased IL-7 mRNA in the skin.
Interestingly, cotransfer of CD8-depleted cells, containing CD4* cells similar in
type and concentration to the 2XNS and CD4-enriched cotransfer populations, were

observed to be associated with a greatly diminished IL-7 mRNA level which may have
explained the inability of this particular cotransfer to control lesions. While it was not

clear why the cotransfer of normal spleen cells containing CD4* cells without CD8~ cells
failed to mediate lesion regression, this cotransfer condition was also associated with a

very low IL-7 mRNA level in the skin. Taken together, it appeared that some basal level

of IL-7 in the skin was necessary for CD4’ T cells to exert their lesion-controlling

capacity. It is again interesting to speculate that the third cell component of this
cotransfer may have gone unregulated when CD8^ cells were removed which might have
acted to downregulate the suppressor CD4' cell population via an IL-7- depleting
mechanism of action. In animals with elevated IL-7 mRNA levels in the skin without the

cotransfer of CD4+ cells, as was seen with the cotransfer of 2XNS enriched for CD8’
cells, lesions were also not controlled. Clearly, regulatory CD4T cells and an elevated IL-

7 mRNA in the skin, but neither alone, were the essential elements for control of

autoimmune Skn effector cells and subsequent lesion control in our model.
It has been reported that culture of regulatory cells in IL-7 could reproducibly

protect recipients from autoimmune disease even when transferred in greatly diminished
numbers (Herbelin et al. 1998). However, we could not demonstrate enhanced lesion
control with the cotransfer of IL-7 cultured unfractionated or CD4-enriched normal
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spleen cells. In fact, the cotransfer of IL-7 cultured CD4-enriched cells diminished lesion

control as compared to noncultured cells of the same type and concentration.

As a

possible explanation, we observed a decreased expression of IL-7R on cultured cells that
might have served to diminish their lesion controlling function via a compromised ability

to respond to IL-7 when cotransferred. It is also possible that the IL-7 concentration in
culture was not optimized for enhancement of regulatory cell activity as in vitro culture

of cells in different concentrations of IL-7 has resulted in different fimctional/cellular
characteristics (Wang et al., 1996; Kung et al., 1998).

In our model, lesions formed in a low IL-7 environment thereby allowing us to

speculate that a low IL-7 level was unlikely to have played a role in SIS cell activation.

However, lesions were controlled by cotransfer of regulatory CD4'T cells that resulted in

an elevated IL-7 skin environment.

This suggested that IL-7 in the skin served a

beneficial role in the enhanced basal proliferation or activity of regulatory T cells. Also,
the elevated IL-7 level may have been sufficient to initiate apoptosis by activation-

induced SIS cell death (AICD) (Wang et al., 1996). The later is supported in that AICD

could be generated in vitro in activated T cells at 100 ng/ml IL-7 (Kung et al., 1998)
while this finding was not observed at 10 ng/ml IL-7 (Wang et al., 1996). Taken together
these results suggested several potential beneficial roles associated with an elevated IL-7
mRNA in the skin of lesion controlling animals.
To determine whether IL-7 was a contributing factor to lesion control in this

autoimmune model, we asked if IL-7 mRNA expression in the skin of lesion-forming
animals could control lesions without regulatory cell cotransfer.
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An IL-7-expressing

plasmid was designed for use in a topically-applied somatic gene therapy and biological

activity of the plasmid-IL-7 product determined. As topical gene delivery using the
pCMV-Tagl vector had not been reported, we determined that pCMV containing the
luciferase reporter could transfect murine skin using the brushing transfection method

(Yu, et al. 1999). The low level presence of luciferase in the skin was in keeping with

other reports that naked plasmid DNA transfects cells poorly (Prud’homme, et al. 2001).
While intramuscular (i.m.) injection of 100-200 pg of plasmid DNA results in systemic

persistence of the plasmid product for

4 months (Chang et al., 1999; Prud’homme et

al., 1999), topical application of naked DNA has been shown to provide peak reporter
activity between 16-72 hours using 3

20 pg of plasmid DNA (Yu et al., 1999).

Although i.m. injection for the expression of plasmid products requires one or several

injections with resultant systemic expression over a long period of time,

topical

application requires only brushing or tape stripping for short term, low level plasmid
expression. An important advantage of short term, low-level plasmid expression is that
application could conceivably be on an ‘as needed’ basis while discontinuance would

result in quick clearance of the plasmid and plasmid product.
While it has been reported that murine skin can be transfected with plasmid

with brushing (Yu et al., 1999), we observed a detrimental lesional effect in our model
when the site destined for lesion formation was brushed. This was not surprising as mild
abrasion of the skin by shaving is an essential component of this autoimmune lesion

forming model. Based on these observations, we elected to apply plasmid with brushing
at sites adjacent to the reactive lesion-forming site. As topical cutaneous IL-7 gene
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delivery for the treatment of cutaneous disorders had not been reported, we selected

plasmid concentrations based on the transfection efficiencies described for plasmid p4241

!

reported by Yu et al. (1999). While these investigators demonstrated optimal luciferase

reporter activity when applying naked plasmid DNA in amounts of approximately 3-20
pg, we observed lesion control with daily application of 5 pg of plasmid DNA placed at
I
i

three adjacent sites to the area destined for lesion formation.

I

plasmid-IL-7 recipients had similarly reduced lesion grades as compared to lesion

In our model system,

controlling animals that had received cotransfer of 2XNS or CD4-enriched normal spleen

cells, while all three conditions had significantly reduced lesions as compared to lesion
forming animals. Taken together, it appeared that IL-7 could mediate Skn-T cell lesion

control with daily application of plasmid-IL-7 without the need for cell cotransfer. While
the transfer of regulatory cells provides explanations with respect to effector T cell

suppression mechanisms, transfer of regulatory spleen cells has little clinical utility

whereas somatic gene therapy has great potential in the treatment of immunologic
disorders. Although we did not pursue application of plasmid at the reactive site due to
the detrimental effect of brushing in our model system, our studies indicated that as little

as 1 - 2.5 pg of plasmid-IL-7 may have been sufficient for lesion control.
We also observed that low-level administration of plasmid-IL-7 did not disrupt
the cytokine milieu of the skin nor did it appear that the plasmid-IL-7 product

collaborated with IL-2, -4, -10, -12, IFN-y or TGF-p to facilitate lesion control. This

corresponded to other in vivo studies demonstrating no cytokine production with

intraperitoneal injection of IL-7 (Geiselhart et al., 2001). Because non-IL-7 cytokine
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levels were unaltered in our studies, somatic gene therapy via IL-7 might avoid
potentially serious cytokine-stimulatory or inhibitory side effects. Further studies are

warranted to determine the toxic threshold of plasmid-IL-7 expression as cutaneous skin
disorders have been observed in transgenic mice (Rich et al., 1993; Uehira et al., 1998).
While we tested plasmid-IL-7 application up to 20 pg of DNA without gross changes
observed in the skin of normal mice, we can only surmise from our IL-7 culture of

regulatory cells prior to cotransfer that their lesion controlling ability might have been
compromised at significantly higher levels of IL-7 in the skin.

Furthermore, negligible levels of endogenous IL-7 mRNA level in plasmid-IL-7
recipient skin and well below that of lesion-forming animals suggested that a homeostatic

mechanism existed for the control of IL-7 levels while also suggesting that plasmid-IL-7

facilitated lesion control independent of endogenously supplied IL-7.

That

administration of the IL-7-expressing plasmid appeared to downregulate the level of

endogenous IL-7, would also suggest that its use would not be additive and therefore
would not promote the development of toxic levels of IL-7 in the skin with proper dosing.
Our use of a CMV promoter, known to function in a variety of cell types, was
advantageous in our model as we detected plasmid movement to the reactive site whereas
the use of a keratinocyte promoter would have been more likely to have expressed the

product of interest only at the site of application. The idea that plasmid could be placed
at unaffected sites adjacent to the intended target site to mediate an immunomodulatory

effect is not totally infeasible when one considers the use of such techniques for wound

healing or immunomodulation of isolated psoriatic skin plaques.
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peripheral placement of plasmid was sufficient to facilitate lesion regression suggesting

that plasmid transfected cells such as dendritic cells will migrate to a site of reactivity.
A role for IL-7 in autoimmune skin lesion control was demonstrated although
we can only speculate on the mechanism of its action. While we used a CMV promoter-

driven plasmid known to be active in many cell types, it is difficult to say whether our
findings were due to a localized and/or systemic response as FLAG-IL-7 mRNA was

isolated from the skin as well as the spleen (data not shown) of plasmid-IL-7 recipients.
We can only hypothesize that plasmid-IL-7 expression in the skin may be associated with

regulatory T cell repopulation in a skin-restricted manner, although we cannot rule out
that plasmid-IL-7 expression in the spleen may have also contributed to regulatory T cell
supply to the skin. FLAG-IL-7 was isolated at sites where plasmid was not applied

suggesting that transfection of a migratory cell had occurred and thus explaining its

presence in the spleen of plasmid-IL- recipients. In vivo IL-7 administration is reported
to increase T cell numbers with acquired functional capacity (Geiselhart et al., 2001).
This further supports our claim that in vivo IL-7 expression in the skin of mice destined to
form lesions was most instrumental in enhancing numbers or activity of regulatory T

cells rather than acting directly on SIS cells to render them anergic or apoptotic. It would
be of interest to determine whether topically applied naked plasmid DNA could facilitate

systemic T cell repopulation in other T cell depleted models or conditions.
Although transgenic mice overexpressing IL-7 have been shown to develop a

progressive cutaneous disorder (Rich et al., 1993) and colitis (Watanabe et al., 1998), we
demonstrated moderate levels of IL-7 mRNA, compared to other amplified cytokines
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analyzed, expressed in the skin of lesion-forming animals was associated with
autoimmune lesion control.

That we were able to demonstrate FLAG-IL-7 by PCR

■

amplification but unable to detect demonstrable levels of FLAG-IL-7 protein by Western
blot (data not shown) or by immunohistochemical staining (data not shown) would

support the claim that low level transfection or rapid IL-7 degradation occurred in our
I

model which resulted in the beneficial low level expression of IL-7 in the skin.

Therefore, in studies demonstrating the beneficial or detrimental effects of IL-7, it may

be important to identify the level of IL-7 associated with these findings as IL-7 is likely

to have bimodal activity as is seen with other regulatory cytokines such as TGF-P, IL-4,
and IL-10 as well as with the inflammatory cytokines (Kalden et al., 1998;
Theofilopoulos et al., 1999; Prud’homme, 1993). Taken together, we can only speculate

that elevated IL-7 expression in the skin may have played an indirect role in suppressor
CD4* cell repopulation, recruitment to the skin and/or enhanced functional capacity while

we could not rule out that IL-7 played a direct role in inducing autoimmune Skn-T cell
anergy or apoptosis.

Ex vivo transfection of cells for transfer using nonreplicating viruses has been
the most commonly used technique for gene therapy.

The use of such viruses of

retroviral or adenoviral origin do, however, have limitations including risk of

contamination, recombination with helper viruses, and complex production and
implementation methods making it somewhat impractical choice for clinical use.
Systemic administration and expression of immunomodulatory agents has been fraught

with unwanted systemic responses when localized targeting of the agent may have been
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more desirable. The use of naked plasmid DNA without viral carriers, or the need for

injection, circumvents these concerns and has many advantages. With respect to the skin,
!

the topical somatic gene therapy-based approach is more apt to provide local expression

■

of regulatory proteins at sites of autoimmune inflammation where their expression would
provide local effects.

Other advantages of plasmid-based gene therapy includes

intracellular synthesis of plasmid products which allows for proper intracellular

processing such as splicing, native configuration protein folding, correct glycosylation
and normal post-translational modifications. Plasmid vectors are easily manipulated and
are able to accommodate virtually any gene or gene derivative while recombinant
plasmids can be produced at large scale in bacteria at a relatively low cost with relatively

long shelf-life. As the administration of DNA vaccines, as well as injection of naked
DNA, may stimulate undesirable immune responses, somatic gene therapy using plasmid

DNA alone in gene delivery has the advantage of circumventing potential host responses.

Previously, delivery of cytokines into the skin without carriers has relied on
methods such as intradermal injection (Furth et al., 1995) and electric pulse (Zhang et al.,

1996) that may have limited clinical relevance. The gene gun (Williams et al., 1991) may
also have limited clinical utility when large areas or frequent treatments are required.

Topical naked plasmid gene delivery of cytokines by mild abrasion and subsequent low
level expression circumvents many of the efficacy and safety concerns associated with

other gene-based treatments while providing a means to potentially transfect large areas

of the skin in a noninvasive, simple and inexpensive manner which supports further

investigation.
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While the mechanisms controlling the topical delivery of naked plasmid DNA are

poorly understood and need to be further investigated, we demonstrated the usefulness of

topical application of naked plasmid-IL-7 DNA in the clinical suppression of
autoimmune skin lesions.

We also demonstrated that brushing allows for DNA

transfection of skin with no need for liposome or viral carriers, sophisticated transport
devices or ex vivo manipulation, and that treatment circumvents host immune responses
as demonstrated by an unaltered cytokine profile. That exogenously supplied plasmid-IL-

7 was capable of downregulating the expression of endogenously produced IL-7
suggested that a feedback mechanism for IL-7 level control existed in the skin that may

be responsive to plasmid-IL-7 dosing. Whereas cotransfer of unfractionated or CD4enriched normal spleen cells was shown to control autoimmune skin lesions, plasmid

based somatic gene therapy for expression of regulatory cytokines, such as in the delivery
of IL-7 to the skin, offers a more cost effective and practical approach to the regulation of

deleterious immune responses. In so much as the manipulation of regulatory and effector
T cells by immunomodulatory proteins can lead to new insights into the treatment of
autoimmune disease, transplant rejection and cancer, topical gene therapy facilitated by

mild abrasion may also represent a technique with potential clinical utility for the
delivery and expression of proteins in the skin toward the treatment of a variety of skin-

related conditions.

■
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APPENDIX A
Primer Sites within the IL-7 Sequence

cttgcaatagcgagctttctctgctgcacatttgtggcttctgtggacatattagtaaccagcggttttagctcccagtctcacagagttgccagagagg
I

100

50

ttagaagtcatttgaaaagcctattagccgaatctttctgatccagaaggccagctggcttctcctgagctactttcaattcgcagcaaccactgatcct
150
200

V

GGTCCAGGTG ACTGGGGAAGACGCTGAGGGTATAAACCC AAACATTG AACCTGAAGACCCAGCGCAAAGTAGAAACTGAAAGTACCCTGCTTACTCTGCC
250 100

V

GGCAGATCCTACGGAAGTTATGGCAAAGff aGAGCGCCTGGGTGGCCGGTGA ATGCATGCGGCCCCTCTTGGGATGGATGGACCAGGCGTGGCGTGGGTG
150 400

AGAGGAGTCAGCTGCCTGAACTGCCCTGCCCAGCACCGGTTTGCGGCCACCCGGTGGATGACCGGGGTCCTGGGAGTGATTATGGGTGGTGAGAGCCGGC
450
500

[FLAG}»
Mat:

-20
Pha NM Vai Ser Pha Arg Tyr He Pha Gly Xie Pro
TCCTGCTGCAGTCCCAGTCATCATGACTACACCCACCTCCCGCAGACC ATG TTC CAT GTT TCT TTT AGA TAT ATC TTT GGA ATT CCT
550
-10
1
******
*10***
*
Pro Leu He Lou Vai Leu Lou
Leu Pro Vai Thr Sor
Ser Ser Glu Cya Mia
K»« Ho Lya Aap Lya Glu Gly Lya Ala Tyr Glu
CCA CTG ATC CTT GTT CTG CTG CCT GTC ACA TCA TCT GAG TGC CAC ATT AAA GAC AAA GAA GGT AAA GCA TAT GAG
60 0
|
' I
8 50

*

20

Endogenous IL-7

30

Sor Vai Lou Het Ho Sor
Ser Ilo Aap Glu Lou Aap Lya Mot Thr Gly Thr Aap Sor Aan Cya Pro Aon Aan Glu Pro
AGT GTA CTG ATG ATC AGC ATC GAT GAA TTG GAC AAA ATG ACA GGA ACT GAT AGT AAT TGC CCG AAT AAT GAA CCA
700
I J
40
50
50
Aan Ph* Ph* Arg Lya Hit Vai Cya Asp Aap Thr Lya Glu Ala Ala Pha Leu Aan Arg Ala Ala Arg Lya Leu Lya
AAC TTT TTT AGA AAA CAT GTA TGT GAT GAT ACA AAG GAA GCT GCT TTT CTA AAT CGT GCT GCT CGC AAG TTG AAG
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_____ 70
•0
Gin Ph* Lou Lya Mot[jAan
Aan tla
tie Ser|Glu Glu Pho
Ph* Aan Vai Hu
Hi» Leu Lau Thr Vai Sac Gin Gly The Gin The Leu
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Val( Aan Cys Thr) Sor Lya Glu Glu Lya Aan Vai Lya Glu Gin Lya Lya Aan Aap Ala
Pha Cya
Leu Lya Arg Leu
GTG AAC TGC ACA AGT AAG GAA GAA AAA AAC GTA AAG GAA CAG AAA AAG AAT GAT GCA TGT TTC CTA AAG AGA CTA
900
950

120
129
Leu Arg Glu He Lya Thr Cya Trp Aan Lya He Lou Lya Gly Ser He CAG
CTG AGA GAA ATA AAA ACT TGT TGG AAT AAA ATT TTG AAG GGC AGT ATA TAA ACAGGACATGTAGTAACAACCTCCAAGAATCT
1000
tactggttcatatacttggagaggttgaaacccttccag .
1050

[AAATAAGCCAAGCAGCTGAGAAATCTACAGTGAGGTAT

gagatgatggacacagaaatgcagctgactgctgccgtcagcatatacatataaagatatatcaactatacagatttttgtaatgcaatcatgtcaactg

1150

1200

CAATGCTTTTAAAACCGTTCCAAATGTTTCTAACACTACAAAGTCTACAAAAAGCAAGGCTATGAAGATTCAGAGTCACCACTGTTTTCTTAGCAAAATG
125U
1200
ArGGTATIGTTAAACATTCATTGGTGAACCACTGGGGGAGTGGAACTGTCCTGTTTTAGACTGGAGATACTGGAGGGCTCACGGTGATGGATAATGCTCT
1J50
1400
tgaaaacaagagtctatcttaaagcagcagcaaaaagaagcttaaggcacttaaggcagcaacaaatgtagttaaatatgaatgtataacacataacttc

1450

1500

AGTAAAGAGCATAGCAGATATTTTTAAATAAAAGTATTTTTAAAGATAGAAATGCACTTATTCCAAAGATACTGAACCTTAGTATTCAGTCGCTTTTGAC
1550
------KOO
acttgtgtataataaagcttatataactgaattttcaatttgaaaagtatatttttaaaagaaaa
1450
1700

177

